FGFR-FC Fusion Proteins and the Use Thereof

Abstract

The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases.

Description

CROSS-REFERENCE TO A RELATED APPLICATION

[0001] The present application is a continuation of co-pending U.S. application Ser. No. 13/842,345, filed Mar. 15, 2013; which is a continuation-in-part of International Application PCT/CN2012/075706, filed May 18, 2012; which claims priority to Chinese Application No. 2011 10132218.9, filed May 20, 2011; all of which are incorporated by reference herein in their entirety, including any figures, tables, nucleic acid sequences, amino acid sequences, or drawings.

[0002] The Sequence Listing for this application is labeled SeqList-10June14-ST25.txt which was created on Jun. 10, 2014 and is 105 KB. The entire content of the sequence listing is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0003] The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases.

BACKGROUND OF THE INVENTION

[0004] Angiogenesis is one of the primary factors resulting in the growth and metastasis of malignant tumors [1]. The process of angiogenesis is regulated by many factors, among which some factors promote angiogenesis, while some factors inhibit angiogenesis, and as a result, the regulation of angiogenesis is a very complicated dynamic process [2]. Anti-angiogenesis treatment is intended to control the growth of a tumor by blocking angiogenic stimulating factors or preventing angiogenesis in the tumor using angiogenesis inhibitors. At present, a large amount of angiogenic stimulating factors are known, such as, for example, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF) etc., which may stimulate the division and differentiation of vascular endothelial cells and the morphogenesis of blood vessels. Among these factors mentioned above, it is now known that VEGF is the most angiogenesis-specific and the most effective growth factor [3, 4].

[0005] In a hypoxic environment inside tumor tissue, VEGFs are secreted by the tumor cells, which induce the division and migration of vascular endotheliocytes, resulting in the establishment of a tumor vascular network. It has been demonstrated that the inhibition of VEGF may prevent angiogenesis, and further inhibit the growth of tumor. For this reason, VEGF and its receptors are important targets for anti-angiogenesis medicaments.

[0006] At present, anti-angiogenesis medicaments demonstrated in clinical trials to have efficacy include Bevacizumab (under the trade name of Avastin), which is able to block VEGF directly and inhibit the tumor angiogenesis. Bevacizumab was approved for marketing by the FDA in 2004, and as a first-line drug for rectal cancer, it is the first marketing-approved drug that plays a role in anticarcinogenesis by inhibiting angiogenesis. Avastin is a humanized anti-VEGF monoclonal antibody, which is produced by Genentech. In a large-scale Phase III clinical trial, the combined therapy by Avastin and chemotherapy may significantly extend the survival time of the patients suffered from many kinds of cancers, including rectal cancer, lung cancer, breast cancer and renal cancer. [5, 6] The clinical success of Avastin is a landmark, demonstrating that the anti-angiogenesis treatment using tumor vascular system as the target is a clinically effective measure and provide a new path for the tumor treatment.

[0007] Besides Avastin, several drugs for anti-VEGF signaling are also in the late phase of human clinical trial and are expected for clinical application in the next several years. Among others, Aflibercept (also called as VEGF-Trap), developed by the Regeneron and Sanofi-Aventis, is now in Phase III clinical trial [7]. An anti-VEGF receptor II (VEGFR2) monoclonal antibody drug IMC-1121B (Imclone) is also in Phase III clinical trial [8]. The amino acid sequence of VEGFR2 is provided in SEQ ID NO: 3 and the nucleotide sequence of VEGFR2 mRNA is provided in SEQ ID NO: 6.

[0008] Great progress has been achieved in the clinical treatment of tumor using anti-VEGF medicament, however, it has also been shown by the clinical trial that the anti-VEGF treatment are also considerably limited. From the point of the effect of tumor treatment, Avastin may extend the half survival time of the colon cancer patient for about 3-4 months [9, 10], and extend the half survival time of the breast cancer patient for about 7-8 months [11], and thus, Avastin cannot effectively inhibit the growth of tumor blood vessel over the long term.

[0009] The primary causes resulting in the failure of anti-VEGF treatment or the appearance of resistance may depend on the regulation of tumor angiogenesis by a plurality of factors. Although VEGF plays an important role in angiogenesis, it is not the only angiogenesis stimulating factor. Meanwhile, owing to the heterogeneity of tumor cells, the complexity of tumor microenvironment and the compensatory response mechanism of body, when the activity of VEGF is inhibited for a long period of time, other angiogenesis stimulating factors would be expressed [12], and thus the growth of tumor blood vessel is no longer dependent on VEGF signaling path.

[0010] The variation of angiogenesis factors expressed by the tumor was studied during anti-VEGFR2 treatment for pancreatic tumor by Prof. Hanahan's group (University of California, San Francisco, US), indicating that the expression of several genes changed during anti-VEGF treatment, in which the expression of FGF-2 significantly increased. It has been shown that the expression of FGF, especially FGF-2, increased significantly in the tumor resistant to anti-VEGF treatment so that angiogenesis was activated again and the tumor repopulation was inhibited after blocking FGF signal pathway [13]. It may be seen that the over-expression of FGF-2 is closely related to the ability of tumor to escape from anti-VEGF treatment.

[0011] Fibroblast growth factor (FGF) is a growth factor family for heparin-binding, and there are 22 family members (FGF 1-14, 16-23) in mammals. FGF plays an important role in many biological functions, for example, cell proliferation, differentiation, migration, angiogenesis and tumorigenesis. Fibroblast growth factor receptor (FGFR) is the receptor that binds the family members of fibroblast growth factor. FGF may bind FGFR and activate the downstream signal pathway, which plays an important role in a physiological and pathological process, such as embryogenesis, development, vasculogenesis, vasodilatation, neuroregulation, ischemia protection, wound healing and tumorigenesis. [14, 15] It has been demonstrated that overexpression of FGF/FGFR in vivo is closely related to many diseases including tumors (such as fibroma, neuroglioma, melanoma, prostate carcinoma, lymphomata, leukaemia, urinary, and system cancer), skeletal system diseases (dwarfism, craniosynostosis, achondroplasia, and acanthosis nigricans) and renal failure. It has been reported that increased expression level of FGF and its receptor may directly promote the survival and proliferation of tumor cells, and the survival of hepatic carcinoma cells is significantly reduced by down-regulation of FGF by siRNA [22].

[0012] At present, few researches focus on the development of new anti-angiogenesis medicament using FGF and its receptor as the target in clinical trials. For example, FP-1039, a fusion protein composed of whole extracellular domain of human FGFR1 and human IgG1 Fc fragment, is developed by a US company Five Prime and now in volunteer recruitment stage of Phase I clinical trail. However, it has been suggested by researches of Wang and Olsen that the first Ig-like domain of the extracellular domain of human FGFR1 and the linking fragment between the first and the second Ig-like domain of the extracellular domain of human FGFR1 may inhibit binding of FGFR1 and FGF [20, 21].

[0013] The tertiary structure of a protein is closely related to its biological function. The FGF binding capacity is directly influenced differences among the conformations of each Ig-like domain of the extracellular domain of FGFR and the linking fragment. Different fusion proteins, composed of the FGFR extracellular domain fragments of various lengths and IgG Fc, are constructed by means of genetic engineering to obtain fusion proteins with different conformations, so that the fusion protein with high efficiency of FGF binding and biological activity can be screened.

[0014] There are four FGFR genes in mammals: fgfR1-fgfR4. Fibroblast growth factor receptor is composed of the extracellular domain, transmembrane domain and intracellular domain. There are many members in FGFR family, which have similar extracellular domain but vary in the ligand binding property and kinase domain. Their extracellular domains include three immunoglobulin-like (Ig-like) domains: the first Ig-like domain, the second Ig-like domain and the third Ig-like domain, and there is a sequence between the first and the second Ig-like domain, which is referred as the intermediate functional sequence of the Ig-like domain of FGFR (IFS for short herein) in this specification. The intermediate functional sequence may comprise one acidic amino acid segment, which is referred as acidic box (AB).

BRIEF SUMMARY

[0015] The present invention provides isolated soluble fusion proteins of fibroblast growth factor receptor (FGFR), which comprise: a part derived from an intermediate functional sequence (also referred to herein as IFS) of an Ig-like domain of FGFR, a second Ig-like domain (also referred to herein as D2) of FGFR, a third Ig-like domain (also referred to herein as D3) of FGFR and an immunoglobulin Fc region.

[0016] In certain embodiments, the part derived from IFS contains no acidic box. In other embodiments, the IFS portion has the amino acid sequence of position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1, or has an amino acid sequence sharing at least 70% identity with the amino acid sequence of position 134 to position 162, position 145 to position 162 or position 151 to position 162 of SEQ ID NO: 1.

[0017] The present invention further relates to a fusion protein, which comprises or consists of: the first Ig-like domain (also referred to herein as D1) of FGFR or a moiety thereof, a part derived from the intermediate functional sequence region of the Ig-like domain of FGFR, the second Ig-like domain of FGFR, the third Ig-like domain of FGFR, and an immunoglobulin Fc region.

[0018] Preferably, the D1 domain or a moiety thereof possesses:

[0019] the amino acid sequence corresponding to position 40 to position 118 of SEQ ID NO: 1, or an amino acid sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity with the sequence of position 40 to position 118 of SEQ ID NO: 1; or the amino acid sequence corresponding to position 77 to position 118 of SEQ ID NO: 1, or an amino acid sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity with the amino acid sequence of position 77 to position 118 of SEQ ID NO:1.

[0020] In one aspect, the present invention provides a fusion protein that comprises or consists of: the intermediate functional sequence region of the Ig-like domain of FGFR or a moiety thereof, the second Ig-like domain of FGFR, the third Ig-like domain of FGFR and immunoglobulin Fc region, wherein:

[0021] the second Ig-like domain of FGFR has the amino acid sequence corresponding to position 163 to position 247 of SEQ ID NO: 1, or an amino acid sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity with the amino acid sequence of position 163 to position 247 of SEQ ID NO: 1; and/or

[0022] the third Ig-like domain of FGFR has the amino acid sequence corresponding to position 270 to position 359 of SEQ ID NO: 1, or an amino acid sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity with the amino acid sequence of position 270 to position 359 of SEQ ID NO: 1.

[0023] The present invention further provides a fusion protein that comprises a region derived from the extracellular domain of FGFR and a immunoglobulin Fc region or composed thereof, wherein the region derived from the extracellular domain of FGFR:

[0024] (1) has the amino acid sequence indicated by positions 358-580 of SEQ ID NO: 9, positions 304-526 of SEQ ID NO: 10, positions 278-500 of SEQ ID NO: 11, positions 246-468 of SEQ ID NO: 12, positions 235-457 of SEQ ID NO: 13, positions 229-451 of SEQ ID NO: 14 or positions 224-446 of SEQ ID NO: 15, or the amino acid sequence encoded by the nucleotide sequence indicated by positions 1074-1740 of SEQ ID NO: 16, positions 912-1578 of SEQ ID NO: 17, positions 834-1500 of SEQ ID NO: 18, positions 738-1404 of SEQ ID NO: 19, positions 705-1371 of SEQ ID NO: 20, positions 687-1353 of SEQ ID NO: 21 and positions 672-1338 of SEQ ID NO: 22;

[0025] (2) comprises or consists of the amino acid sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity with the amino acid sequence indicated by positions 358-580 of SEQ ID NO: 9, positions 304-526 of SEQ ID NO: 10, positions 278-500 of SEQ ID NO: 11, positions 246-468 of SEQ ID NO: 12, positions 235-457 of SEQ ID NO: 13, positions 229-451 of SEQ ID NO: 14 or positions 224-446 of SEQ ID NO: 15; or

[0026] (3) comprises or consists of the amino acid sequence encoded by a nucleotide sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity with the nucleotide sequence indicated by positions 1074-1740 of SEQ ID NO: 16, positions 912-1578 of SEQ ID NO: 17, positions 834-1500 of SEQ ID NO: 18, positions 738-1404 of SEQ ID NO: 19, positions 705-1371 of SEQ ID NO: 20, positions 687-1353 of SEQ ID NO: 21 or positions 672-1338 of SEQ ID NO: 22.

[0027] The present invention further relates to a fusion protein, wherein the protein:

[0028] (1) comprises the amino acid sequence indicated by any one of SEQ ID NOs: 9-15, or an amino acid sequence encoded by the nucleotide sequence indicated by any one of SEQ ID NOs: 16-22;

[0029] (2) comprises or consists of the amino acid sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity, with the amino acid sequence indicated by any one of SEQ ID NOs: 9-15; or

[0030] (3) comprises or consists of the amino acid sequence encoded by the nucleotide sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity, with the nucleotide sequence indicated by any one of SEQ ID NOs: 16-22.

[0031] Preferably, in the fusion protein of the present invention, the immunoglobulin Fc region is human IgG1 Fc region, and more preferably, it comprises:

[0032] the amino acid sequence corresponding to SEQ ID NO: 7, or the amino acid sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity, with the amino acid sequence of SEQ ID NO: 7; or

[0033] the amino acid sequence encoded by the nucleotide sequence corresponding to SEQ ID NO: 8, or the amino acid sequence encoded by the nucleotide sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity, with the nucleotide sequence of SEQ ID NO: 8.

[0034] In one embodiment of the present invention, the immunoglobulin Fc region is located at the C-terminus of the fusion protein.

[0035] The present invention further provides a fusion protein precursor comprising a secretory signal peptide region, for example, VEGFR1 signal peptide region, and preferably, the secretory signal peptide region has the amino acid sequence of position 1 to position 26 of SEQ ID NO: 2 or the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 23. Preferably, the signal peptide region is located at the N-terminus of the precursor. The nucleotide sequence of VEGFR1 mRNA is provided in SEQ ID NO: 5.

[0036] In another aspect of the present invention, an isolated nucleic acid molecule that encodes the fusion protein or the precursor of the fusion protein of the present invention is provided. Preferably, the nucleic acid molecule comprises the nucleotide sequence indicated by any one of SEQ ID NOs: 16-22.

[0037] The present invention provides a fusion protein that sequentially comprises from the N-terminus to the C-terminus: portions derived from IFR, D2, D3 and immunoglobulin Fc region.

[0038] The domains and/or regions involved in the fusion protein of the present invention can be linked directly and/or by a linker. In one embodiment, the region derived from the extracellular domain of FGFR and immunoglobulin Fc region are linked directly. In another embodiment, the region derived from the extracellular domain of FGFR and immunoglobulin Fc region are linked by a linker.

[0039] In one aspect, the fusion protein of the present invention inhibits angiogenesis. In another aspect, the fusion protein of the present invention binds FGF, preferably FGF2, in vivo and/or in vitro. In another aspect, the fusion protein of the present invention inhibits tumor cells directly.

[0040] The present invention further relates to an FGFR-Fc fusion protein that comprises a portion derived from the extracellular domain of FGFR and a portion derived from immunoglobulin Fe region. Particularly, the portion derived from the extracellular domain of FGFR is derived from the extracellular domain of FGFR1. Preferably, the immunoglobulin Fc region is a human immunoglobulin Fc region, for example, a human IgG1 Fc region. In one aspect of the present invention, the FGFR-Fc fusion protein of the present invention has the capacity of binding and/or antagonizing FGF, and thus, inhibit angiogenesis.

[0041] In the FGFR-Fc fusion protein of the present invention, the portion derived from the extracellular domain of FGFR may comprise one or more selected from the group consisting of: D1 domain or a moiety thereof, the portion derived from IFS, D2 domain or a moiety thereof and D3 domain or a moiety thereof.

[0042] In one embodiment, the part derived from the extracellular domain of FGFR may comprise D1 or a moiety thereof, the part derived from IFS, D2 domain and D3 domain.

[0043] In another embodiment, the part derived from the extracellular domain of FGFR may comprise the part derived from IFS, D2 domain and D3 domain, and preferably, the part derived from IFS has the amino acid sequence corresponding to position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1.

[0044] In some embodiments, the FGFR-Fc fusion protein of the present invention contains no D1 or a moiety thereof. In some other embodiments, the FGFR-Fc fusion protein of the present invention contains no part from IFS other than the amino acid sequence corresponding to position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1.

[0045] In some embodiments of the present invention, the order from the N-terminus to the C-terminus of each region and/or each domain involved in the FGFR-Fc fusion protein may be any order. In some other embodiments, the order can be as shown in FIG. 1. In some other embodiments, the order may be different from the order shown in FIG. 1.

[0046] In some embodiments, the FGFR-Fc fusion protein of the present invention further comprises one or more intrachain disulfide bonds, and preferably, comprises one or more intrachain disulfide bonds in the Ig-like domain.

[0047] In one aspect of the present invention, the FGFR-Fc fusion protein can be produced by expression of the nucleic acid comprising the nucleotide sequence indicated by any one of SEQ ID NOs: 16-22 in a mammalian cell line. The mammalian cell line can be, for example, a CHO cell line.

[0048] In another aspect of the present invention, a vector comprising the nucleic acid molecule of the present invention is provided.

[0049] In another aspect of the present invention, cells, such as CHO cells, transfected by the vector are provided.

[0050] In another embodiment of the present invention, a pharmaceutical composition, which comprises the fusion protein, the nucleic acid molecule, the vector, or the cells of the present invention, as well as a pharmaceutically acceptable carrier, is also provided.

[0051] In another aspect, the present invention provides a method for producing the angiogenesis-inhibitory fusion protein, which is carried out by expressing the fusion protein of the present invention in prokaryotic cells or eukaryotic cells, especially, in mammalian cell lines.

[0052] The present invention further provides a method for producing the angiogenesis-inhibitory fusion protein, which is carried out by expressing the nucleic acid molecule of the present invention in a mammalian cell. The mammalian cell line can be, for example, a CHO cell line.

[0053] In another aspect of the present invention, a method for inhibition of angiogenesis is provided, which comprises administering, to a subject in need thereof, an angiogenesis-inhibiting effective amount of the FGFR-Fc fusion protein, the nucleic acid molecule encoding the protein, the vector comprising the nucleic acid molecule and/or a pharmaceutical composition comprising any one of these materials. Preferably, the method is carried out in a mammal.

[0054] In another aspect of the present invention, a method for the treatment and/or prevention of a tumor in a mammal is provided. This method comprises administering, to a need of such treatment, a therapeutically or preventively effective amount of the FGFR-Fc fusion protein, the nucleic acid molecule encoding the protein, the vector comprising the nucleic acid molecule, and/or a pharmaceutical composition comprising any one of these materials. Preferably, the tumor is a solid tumor.

[0055] In another aspect, the present invention provides a method for the treatment or prevention of ophthalmic angiogenesis-related diseases in mammals. This method comprises administering, to a subject in need of such treatment or prevention, a therapeutically or preventively effective amount of the FGFR-Fc fusion protein, the nucleic acid molecule encoding the protein, the vector comprising the nucleic acid molecule, and/or a pharmaceutical composition comprising any one of these materials. Preferably, the ophthalmic angiogenesis-related disease is age-related macular degeneration.

[0056] The present invention further relates to use of the FGFR-Fc fusion protein, the nucleic acid molecule encoding the protein, the vector comprising the nucleic acid molecule, and/or a pharmaceutical composition comprising any one mentioned above according to the present invention in the manufacture of a medicament for inhibiting angiogenesis.

[0057] Furthermore, the present invention further relates to use of the FGFR-Fc fusion protein, the nucleic acid molecule encoding the protein, the vector comprising the nucleic acid molecule, and/or a pharmaceutical composition comprising any one mentioned above according to the present invention in manufacture of a medicament for the treatment or prevention of angiogenesis-related diseases, and preferably, the angiogenesis-related disease is a tumor or ophthalmic angiogenesis-related disease.

[0058] In the disclosure, only some specific embodiments claimed for protection are illustrated by way of example, in which the technical features described in one or more technical proposals can be combined with any one or more technical proposals, and these technical proposals obtained by combination are also within the scope of this application, as if these technical proposals obtained by combination were already specifically described in the disclosure.

[0059] It should be understood that the description below is only illustrated by way of example for the technical solutions claimed for protection by the present invention, and not regarded as any limitation on these technical solutions. The protection scope of the present invention shall be defined by the claims as appended.

BRIEF DESCRIPTION OF THE FIGURES

[0060] FIG. 1 is a structural representation of a FGFR1-Fc fusion protein. The FGFR1-Fc fusion protein is represented by a solid line, and a deleted amino acid is represented by a dashed line; the antibody-like domain is represented by a circle; different antibody-like domains are represented by numbers 1-3; a disulfide bond is represented by s s; human IgG1 Fe is represented by a grey box; VEGFR1 signal peptide is represented by SP; the acidic box sequence is represented by a box with the letters AB.

[0061] FIG. 2 shows a comparison of FGF-2 binding among various FGFR1-Fc fusion proteins. Binding of heparin (100 ng/mL) containing FGF-2 (50 ng/mL) or FGF-2 (50 ng/mL) alone to each FGFR1-Fc fusion protein (20 ng/mL) is detected by ELISA.

[0062] FIG. 3 shows SDS-PAGE of 26# FGFR1-Fc fusion protein.

[0063] FIG. 4 shows the binding of FGF-2 to a gradient concentration of 26# FGFR1-Fc fusion protein.

[0064] FIG. 5 shows the affinity between 26# FGFR1-Fc fusion protein and FGF-2.

[0065] FIG. 6 shows the effect of 26# FGFR1-Fc fusion protein on the HUVEC cell division induced by FGF-2.

[0066] FIG. 7 shows the anti-tumor efficacy of FGFR-Fc in renal carcinoma model

[0067] FIG. 8 shows the anti-tumor efficacy of FGFR-Fc in lung carcinoma model

BRIEF DESCRIPTION OF THE SEQUENCES

[0068] SEQ ID NO:1 is an amino acid sequence of human FGRF1.

[0069] SEQ ID NO:2 is an amino acid sequence of human VEGFR1.

[0070] SEQ ID NO:3 is an amino acid sequence of human VEGFR2.

[0071] SEQ ID NO:4 is a nucleotide sequence of human FGFR1.

[0072] SEQ ID NO:5 is a nucleotide sequence of human VEGFR1.

[0073] SEQ ID NO:6 is a nucleotide sequence of human VEGFR2.

[0074] SEQ ID NO:7 is an amino acid seq of human IgG Fc.

[0075] SEQ ID NO:8 is a DNA seq of human IgG Fe.

[0076] SEQ ID NO:9 is a #19 fusion protein.

[0077] SEQ ID NO:10 is a #13 fusion protein.

[0078] SEQ ID NO:11 is a #22 fusion protein.

[0079] SEQ ID NO:12 is a #23 fusion protein.

[0080] SEQ ID NO:13 is a #26 fusion protein.

[0081] SEQ ID NO:14 is a #29 fusion protein.

[0082] SEQ ID NO:15 is a #8 fusion protein.

[0083] SEQ ID NO:16 is a DNA seq of #19 fusion protein.

[0084] SEQ ID NO:17 is a DNA seq of #13 fusion protein.

[0085] SEQ ID NO:18 is a DNA seq of #22 fusion protein.

[0086] SEQ ID NO:19 is a DNA seq of #23 fusion protein.

[0087] SEQ ID NO:20 is a DNA seq of #26 fusion protein.

[0088] SEQ ID NO:21 is a DNA seq of #29 fusion protein.

[0089] SEQ ID NO: 22 is a DNA seq of #8 fusion protein.

[0090] SEQ ID NO:23 is a DNA seq of VEGFR1 signal peptide.

[0091] SEQ ID NO:24 is a forward primer DNA seq of #19 fusion protein.

[0092] SEQ ID NO:25 is a forward primer of DNA seq of #13 fusion protein.

[0093] SEQ ID NO:26 is a forward primer DNA seq of #22 fusion protein.

[0094] SEQ ID NO:27 is a forward primer DNA seq of #23 fusion protein.

[0095] SEQ ID NO:28 is a forward primer DNA seq of #26 fusion protein.

[0096] SEQ ID NO:29 is a forward primer DNA seq of #29 fusion protein.

[0097] SEQ ID NO:30 is a forward primer DNA seq of #8 fusion protein.

[0098] SEQ ID NO:31 is a reverse primer DNA seq of FGFR1.

[0099] SEQ ID NO: 32 is a forward primer DNA seq of human IgG Fc.

[0100] SEQ ID NO:33 is a reverse primer DNA seq of human IgG Fc.

DETAILED DESCRIPTION

Definitions

[0101] Unless otherwise defined, all scientific terms used herein have the same meaning as commonly understood by those skilled in the art. With regard to the definitions and terms in the art, reference may be made to Current Protocols in Molecular Biology (Ausubel) by the skilled one. Standard three- and/or one-letter code used for expressing one of 20 common L-amino acids in the art are adopted as the abbreviation of amino acid residues.

[0102] Although the number ranges and approximate parameter values are given in a broad range in the present invention, all numbers in the specific examples are described as precise as possible. However, certain errors can exist in any numerical values, which may result from, for example, the standard deviation during the measurement. Additionally, all ranges disclosed herein encompass any and all possible subranges contained therein. For example, it should be understood that the range "from 1 to 10" as described herein encompasses any and all possible subranges between the minimum 1 and the maximum 10 (including the endpoints). Additionally, it should be understood that any reference referred as "incorporated herein" is incorporated in its entirety.

[0103] Additionally, it should be noted that unless otherwise clearly and explicitly stated, the singular form includes the plural referent, as used in the present invention. The term "or" and the term "and/or" are used interchangeably, unless otherwise clearly indicated in the context.

[0104] As used herein, the term "Fc", "Fc region", "Fc fragment" or "immunoglobulin Fc region" refers to the crystallizable fragment of immunoglobulin, and in the present invention, said Fc region is preferably the human IgG1 Fc region.

[0105] The term "Fc fusion protein" refers to the antibody-like molecule that incorporates the binding specificity of a heterologous protein and the effector function of a constant region of an immunoglobulin. In terms of the molecular structure, a Fc fusion protein comprises the amino acid sequence having the required binding specificity and the sequence of a constant region of an immunoglobulin. A Fc fusion protein molecule generally comprises a binding site of a receptor or a ligand. The sequence of immunoglobulin constant region may be derived from any immunoglobulin, for example, IgG-1, IgG-2, IgG-3 or IgG-4 subtype, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

[0106] The term "soluble" protein as used herein refers to a protein that may be dissolved in an aqueous solution at a biologically relevant temperature, pH level and osmotic pressure. The "soluble fusion protein" as used herein is intended to mean that the fusion protein does not contain a transmembrane region or an intracellular region.

[0107] As used herein, the term "isolated" refers to a substance and/or entity that: (1) is isolated from at least some components which is present when initially produced (in natural environment and/or in an experiment device) and related thereto and/or (2) is produced, prepared and/or manufactured artificially. The isolated substance and/or entity may be isolated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, about 99%, substantially 100% or 100% other components related to it initially.

[0108] The terms "part," "fragment," or "portion" interchangeably refer to a part of polypeptide, nucleic acid or other molecular constructs.

[0109] The term "Ig-like domain" as used herein refers to immunoglobulin-like domain, which may be found in a plurality of protein families and involved in many biological functions, including cell-cell recognition, cell surface receptor, immune function and the like.

[0110] Fibroblast growth factor (FGF) is a heparin-binding growth factor family that has 22 family members in mammals (FGF 1-14, 16-23). FGF is involved in many important biological functions, such as cell multiplication, differentiation, migration, angiogenesis and tumorigenesis. FGF exerts many biological functions by binding and activating the cell surface FGF receptor (FGFR). (See, for example, Eswarakumar et al. Cytokine Growth Factor Rev. 16: 139-149, 2005).

[0111] Fibroblast growth factor receptor (FGFR) is the receptor that binds the family members of fibroblast growth factor. A part of fibroblast growth factor receptor is involved in the disease process. In mammals, there are 4 FGFR genes: fgfR1-fgfR4. The fibroblast growth factor receptor is composed of an extracellular domain, transmembrane domain, and intracellular domain. The members in FGFR family can differ from each other in the term of ligand binding properties and kinase domains. However, the extracellular domains thereof are similar. There are three immunoglobulin-like (Ig-like) domains contained in their extracellular domains: the first Ig-like domain, the second Ig-like domain and the third Ig-like domain, and there is also a sequence contained between the first and the second Ig-like domain. The sequence contained between the first and the second Ig-like domain is referred to herein as the intermediate functional sequence region of the Ig-like domain of FGFR. Said intermediate regulation sequence comprises a region of acidic amino acids, referred as the acidic box (AB).

[0112] As used herein, the term "the first Ig-like domain of FGFR" or "the first Ig-like domain" refers to the first Ig-like domain in the protein FGFR from the N-terminus, which has, for example, the amino acid sequence corresponding to position 40 to position 118 of SEQ ID NO: 1. Similarly, the term "the second Ig-like domain of FGFR" or "the second Ig-like domain" refers to the second Ig-like domain in the protein FGFR from the N-terminus, which has, for example, the amino acid sequence corresponding to position 163 to position 247 of SEQ ID NO: 1; the term "the third Ig-like domain of FGFR" or "the third Ig-like domain" refers to the first Ig-like domain in the protein FGFR from the N-terminus, which has, for example, the amino acid sequence corresponding to position 270 to position 359 of SEQ ID NO: 1.

[0113] Preferably, the FGFR is FGFR1, and the first Ig-like domain of FGFR is the first Ig-like domain of FGFR1, and the second Ig-like domain of FGFR is the second Ig-like domain of FGFR1, and the third Ig-like domain of FGFR is the third Ig-like domain of FGFR1.

[0114] A part of sequence of hFGFR1 is given as follows, in which each Ig-like domain is shown in shaded area sequentially, see GenBank AAH15035.1.

TABLE-US-00001 MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDL LQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYA CVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETDNTKPNPVA ##STR00001## ##STR00002## ##STR00003## ##STR00004## ##STR00005##

[0115] The amino acid sequence of FGFR1 may be found in SEQ ID NO: 1, and its encoding nucleotide sequence may be found in SEQ ID NO: 4.

[0116] As used herein, the term "the intermediate functional sequence region of the Ig-like domain of FGFR" or "the intermediate functional sequence of the Ig-like domain of FGFR" or "IFS" refers to the sequence between the first Ig-like domain and the second Ig-like domain in the protein FGFR, and preferably, IFS sequence has the amino acid sequence corresponding to position 118 to position 162 of SEQ ID NO: 1.

[0117] Unexpectedly, in accordance with the present invention, it has been found that there is a significant effect of the intermediate functional sequence region on the function of the Ig-like domain. In some embodiments of the present invention, the part derived from the intermediate functional sequence region contains no acidic box. More preferably, the part derived from IFS has the amino acid sequence corresponding to position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1.

[0118] The protein FGFR is preferably FGFR1 (SEQ ID NO: 1), especially the protein FGFR1. The amino acid sequence of the human FGFR1 is shown in SEQ ID NO: 1, and its cDNA sequence is shown in SEQ ID NO: 4.

[0119] The term "FGFR" as used herein refers to fibroblast growth factor receptor, which may be FGFR1, FGFR2, FGFR3 and/or FGFR4. Preferably, the FGFR of the present invention is FGFR1, more preferably, human FGFR1.

[0120] As used herein, the term "degenerate variant" means that the degenerate variant comprises a degenerate change at the third position of the amino acid codon so that degenerate variants encode the same amino acid, for example the wobble position of a triplet code comprising one or more changed variants (also referred as synonymous variant).

[0121] As used herein, the term "subject" refers to mammals, such as humans. It also includes other animals, including domesticated animals (such as dogs and cats), livestock (such as cattle, sheep, pigs and horses) or experimental animals (such as monkeys, rats, mice, rabbits and guinea pigs).

[0122] As used herein, the term "percentage identity," "homology," or "identity" referd to the sequence identity between two amino acid sequences or nucleic acid sequences. The percentage identity may be determined by alignment between two sequences, and the percentage identity refers to the amount of the same residue (i.e., amino acid or nucleotide) at the same position in the aligned sequences. Sequence alignment and comparison may be performed using standard algorithms in the art (for example Smith and Waterman, 1981, Adv. Appl. Math. 2: 482; Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443; Pearson and Lipman, 1988, Proc. Natl. Acad. Sci., USA, 85: 2444) or by the computerized versions of these algorithms (Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive, Madison, Wis.). Computerized versions that are publicly available include BLAST and FASTA. Additionally, ENTREZ available through National Institutes of Health (Bethesda Md.) may be used for sequence alignment. When BLAST and GAP-BLAST are used, default parameters for each program (for example, BLASTN, available on the website of National Center for Biotechnology Information) may be used. In one embodiment, the percentage identity between two sequences may be determined using GCG with a gap-weight of 1 so that the giving weight of each amino acid gap seems as if it is a single amino acid mismatch between two sequences. Alternatively, ALIGN (version 2.0), which is a part of GCG (Accelrys, San Diego, Calif.) Sequence Alignment Software Package, may be used.

[0123] As used herein, the term "hybridization" refers to the process by which a stable double-stranded polynucleotide is formed by non-covalent bonding between two single stranded polynucleotides. The term "hybridization" also may refer to triple-stranded hybridization. The double stranded polynucleotide (generally) produced is the "hybrid" or "duplex". "The condition for hybridization" generally includes a salt concentration lower than about 1 M, and more generally, lower than about 500 mM, and lower than about 200 mM. The hybridization temperature may be as low as 5.degree. C., but it usually higher than about 22.degree. C., and more usually higher than about 30.degree. C., and preferably higher than about 37.degree. C. Hybridization is usually carried out under strict conditions (i.e., the conditions under which the probe will hybridize to its target sequence). Strict hybridization conditions are dependent on the sequence and will be varied under different conditions. Higher hybridization temperature will be probably required by longer segments for specific hybridization. Since the hybridization stringency may be influenced by other factors (including base composition and length of the complementary strand, the presence of organic solvent and the degree of base mismatch), the combination of parameters is more important than the absolute value of any single parameter. Generally, the strict condition is selected as 5.degree. C. lower than the Tm of the sequence under certain ionic strength and pH. Exemplary strict conditions include pH 7.0 to 8.3, sodium ion (or other salts) concentration of at least 0.01 M to no more than 1 M and temperature of at least 25.degree. C. For strict conditions, see, for example Sambrook, Fritsche and Maniatis. "Molecular Cloning A laboratory Manual", 2.sup.nd edition, Cold Spring Harbor Press (1989) and Anderson "Nucleic Acid Hybridization", 1.sup.st edition, BIOS Scientific Publishers Limited (1999), which are incorporated herein by reference for all purposes mentioned above.

[0124] As used herein, the terms "linker," "peptide linker," "linking sequence," and "linker sequence" refer to a short amino acid sequence by which individual domain and/or region involved in the present fusion protein are linked together. The length of the short amino acid sequence is generally 1-20 amino acids, and preferably, 2-10 amino acids.

[0125] As used herein, the term of "the amino acid sequence corresponding to SEQ ID NO: N" in a fusion protein or part or domain means that the fusion protein or part or domain has the amino acid sequence substantially as indicated by SEQ ID NO: N, and preferably, containing no more than 1, 2, 3, 4, 5, 10 or 20 substitutions, additions, and/or deletions of amino acids, and preferably, the fusion protein or part or domain shares at least 70%, 80%, 90%, 93%, 95%, 97%, 98% or 99% identity with the amino acid sequence of SEQ ID NO: N, and more preferably, said fusion protein or part or domain has the amino acid sequence as indicated by SEQ ID NO: N.

[0126] As used herein, the term "FGFR-Fc fusion protein" refers to a fusion protein that comprises the part derived from the extracellular domain of FGFR and the part derived from the immunoglobulin Fc region, wherein the part derived from the extracellular domain of FGFR may: (1) comprise the amino acid sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity, with the amino acid sequence indicated by any one of SEQ ID NOs: 9-15 or composed thereof; (2) comprise the amino acid sequence encoded by the nucleotide sequence sharing at least 70% identity, preferably at least 80%, 90%, 93%, 95%, 97%, 98% or 99% identity, with the nucleotide sequence indicated by any one of SEQ ID NOs: 16-22 or composed thereof; or (3) possess the amino acid sequence indicated by any one of SEQ ID NOs: 9-15, or the amino acid sequence encoded by the nucleotide sequence indicated by any one of SEQ ID NOs: 16-22.

[0127] In some preferable embodiments, the FGFR-Fc fusion protein may be encoded by a nucleic acid, in which the nucleotide sequence encoding the part derived from the extracellular domain of FGFR comprises the sequence of which a complementary sequence is hybridized with the nucleotide sequence as indicated by any one of SEQ ID NOs: 16-22 under stringent conditions, or comprises a degenerative variant of the nucleotide sequence as indicated by any one of SEQ ID NOs: 16-22. In some preferable embodiments, the nucleotide sequence encoding the immunoglobulin Fc region comprises the sequence of which a complementary sequence is hybridized with the nucleotide sequence indicated by SEQ ID NO: 8 under stringent conditions, or comprises a degenerative variant of the nucleotide sequence indicated by SEQ ID NO: 8.

[0128] In other preferable embodiments, the FGFR-Fc fusion protein includes the FGFR-Fc fusion protein variant. In one embodiment, the variant includes the variant that contains no more than 2, 3, 4, 5 or 10 substitutions, additions or deletions of amino acid in the part derived from IFS corresponding to the amino acid sequence indicated by position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1, and preferably, the variant retains the angiogenesis-inhibitory capacity. In another embodiment, the variant contains no more than 2, 3, 4, 5, 10 or 20 substitutions, additions and/or deletions of amino acids in the D2 domain corresponding to the amino acid sequence indicated by position 163 to position 247 of SEQ ID NO: 1, and preferably, the variant retains the angiogenesis-inhibitory capacity. In another embodiment, the variant contains no more than 2, 3, 4, 5, 10 or 20 substitutions, additions and/or deletions of amino acid in D3 domain corresponding to the amino acid sequence indicated by position 270 to position 359 of SEQ ID NO: 1, and preferably, the variant retains the angiogenesis-inhibitory capacity. In another embodiment, the substitution, addition, or deletion is located at the linker or the linking part.

[0129] In addition to the naturally occurring modifications in the part derived from the extracellular domain of FGFR and the part derived from immunoglobulin Fc region, other post-translational modifications may also be comprised in the FGFR-Fc fusion protein. Such modifications include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, esterification and acylation. As a result, non-amino acid components may exist in the modified FGFR-Fc fusion protein. These components may be, for example, polyethylene glycol, lipid, polysaccharide or monosaccharide, or phosphoric acid. The effect of such non-amino acid components on the function of the FGFR-Fc fusion protein may be tested as described for other FGFR-Fc fusion protein variants herein. When the FGFR-Fc fusion protein is produced in a cell, post-translational processing is also possibly important for correct folding and/or protein function. Special cell machines and unique mechanisms exist in different cells (for example CHO, HeLa, MDCK, 293, WI38, NIH-3T3 or HEK293) for these post-translational activities, and different cells may be selected by the skilled artisan to improve modification and processing of FGFR-Fc fusion protein.

[0130] The fusion protein as described herein may be produced by any method known in the art. For example, it may be produced by chemical synthesis or from nucleic acid expression. The peptides used in the present invention may be easily prepared according to the established standard liquid, or preferably, solid phase peptide synthesis method known in the art (see, for example J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, 2.sup.nd edition, Pierce Chemical Company, Rockford, Ill. (1984), in M. Bodanzsky, and A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York (1984)). The fusion protein may be produced by the techniques known in the art so that one or more intramolecular crosslinkings may be formed between the cysteine residues located in the polypeptide sequence expected to be comprised in the protein (see, for example U.S. Pat. No. 5,478,925). In addition, general modifications may be performed to the protein described herein by adding, for example, cysteine or biotin to the C-terminus or N-terminus of the protein.

[0131] As used herein, "therapeutically effective amount" or "effective amount" refers to a dosage that is sufficient to provide a benefit to the subject to whom it is administrated. The administrated dosage, the rate and the time course of administration are dependent on the condition of the patient and the severity of the disease. Finally, the physician is responsible for the prescription (for example decision on the dosage etc.) and will make a decision for the treatment, usually by considering the disease treated, individual condition of the patient, position of delivery, the method for administration and other factors known to the physician.

[0132] A series of isolated soluble FGFR-Fc fusion proteins have been constructed according to the present invention, which may bind FGF and effectively inhibit the cell division induced by FGF. The fusion protein preferably comprises: the part derived from IFS, D2, D3 and immunoglobulin Fc region.

[0133] Unexpectedly, it has also been found that the binding of FGF by the fusion protein is significantly influenced by the length of the part derived from IFS. Preferably, the part derived from IFS comprises no acidic box, and more preferably, it has the amino acid sequence corresponding to position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1. In some preferable embodiments, the part derived from IFS comprises the fusion protein corresponding to the amino acid sequence indicated by position 145 to position 162 of SEQ ID NO: 1, which has extremely high FGF affinity and potential to effectively inhibit cell division induced by FGF.

[0134] In some embodiments of the present invention, a soluble FGFR-Fc fusion protein is provided, which comprises: D1, a part derived from IFS, D2, D3 and an immunoglobulin Fc region. Preferably, the part derived from IFS comprises no acidic box, and more preferably, it has the amino acid sequence corresponding to position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1.

[0135] In some other embodiments of the present invention, a soluble FGFR-Fc fusion protein is provided, which comprises: a part of D1, a part derived from IFS, D2, D3 and an immunoglobulin Fc region. Preferably, the part derived from IFS comprises no acidic box, and more preferably, it has the amino acid sequence corresponding to position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1.

[0136] In some other embodiments of the present invention, a soluble FGFR-Fc fusion protein is provided, which comprises: a part derived from IFS, D2, D3 an immunoglobulin Fc region. Preferably, the part derived from IFS comprises no acidic box, and more preferably, it has the amino acid sequence corresponding to position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1.

[0137] In some other embodiments of the present invention, a soluble FGFR-Fc fusion protein is provided, which is sequentially composed of, from the N-terminus to the C-terminus, a part derived from IFS, D2, D3 and an immunoglobulin Fc region. Preferably, the part derived from IFS comprises no acidic box, and more preferably, it has the amino acid sequence corresponding to position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1.

[0138] In some other embodiments of the present invention, an FGFR-Fc fusion protein is provided, which can inhibit tumor cells directly or indirectly. Preferably, the FGFR-Fc fusion protein of the present invention inhibits tumor cells directly. More preferably, the growth of tumor cells is inhibited by the FGFR-Fc fusion protein of the present invention by at least 10%, 20%, 30%, 40%, 50%, 80%, 90% or 95%. The tumor cells may be any tumor cells, for example, leukemia, lung cancer, liver cancer, head and neck cancer, stomach cancer, bladder cancer, or carcinoma of uterine or cervix etc. Preferably, the inhibition is achieved by direct binding to tumor cells.

[0139] In some embodiments, the present invention includes use of (i) a FGFR-Fc fusion protein, or (ii) a polynucleotide encoding such fusion protein, in the preparation of the compositions or medicaments for the treatment of diseases mediated by, or related to, angiogenesis. For example, in one embodiment, the present invention provides use of (i) FGFR-Fc fusion protein, or (ii) a polynucleotide encoding such fusion protein in the preparation of a medicament as an angiogenesis inhibitor.

[0140] In some embodiments, the FGFR-Fc fusion protein according to the present invention may be produced by the expression of the nucleotide sequence as indicated by any one of SEQ ID NOs: 16-22 in a mammalian cell line. The mammalian cell line can be, for example, a CHO cell line.

[0141] Additionally, in the present invention, the FGFR-Fc fusion protein as described below is provided, in which a part derived from the extracellular domain of FGFR may be fused with the immunoglobulin Fc region with or without a linker.

[0142] In some other embodiments, the present invention includes the isolated nucleic acid molecules encoding the FGFR-Fc fusion protein, and the present invention also includes use of these molecules in the manufacture of a medicament. The nucleic acid may be recombinant, synthetic or produced by any available methods in the art, and the methods include cloning by means of using standard technique.

[0143] In some other embodiments, the present invention includes a vector comprising the nucleic acid molecule of the present invention. The vector may be an expression vector, in which the nucleic acid is operatively linked to a control sequence that is able to facilitate the expression of the nucleic acid in a host cell. A plurality of vectors may be used. For example, suitable vectors may include virus (for example poxvirus, adenovirus, baculovirus etc.); or yeast vectors, bacteriophages, chromosomes, artificial chromosomes, plasmids, and cosmids.

[0144] In some embodiments, the present invention further includes the cells transfected by these vectors so that the FGFR-Fc fusion protein is expressed. The host cell suitable for the present invention may be a prokaryotic cell or eukaryotic cell. They include bacteria, for example E. coli; yeast; insect cells; and mammalian cells. The mammalian cell lines that may be used include, but are not limited to, Chinese Hamster Ovary (CHO) cells, baby hamster kidney cells, NSO mouse myeloma cells, monkey and human cell lines, and derivate cell lines thereof

[0145] In another aspect of the present invention, a method for angiogenesis inhibition is provided, comprising administering the FGFR-Fc fusion protein of the present invention to the subject in need thereof. Preferably, the method is carried out in a mammal.

[0146] In another aspect of the present invention, a method for binding FGF in vitro or in vivo is provided, which comprises contacting FGF to the fusion protein according to the present invention.

[0147] In another aspect of the present invention, a method for the treatment or prevention of tumors in a mammal is provided, which comprises administering the FGFR-Fc fusion protein of the present invention to the subject in need thereof. Preferably, the tumor is a solid tumor.

[0148] In another aspect of the present invention, a method for the treatment or prevention of ophthalmic angiogenesis-related diseases in a mammal is provided, which comprises administering the FGFR-Fc fusion protein of the present invention to the subject in need thereof. Preferably, the ophthalmic angiogenesis-related disease is age-related macular degeneration.

[0149] The present invention also relates to use of the FGFR-Fc fusion protein in the preparation of medicaments for angiogenesis inhibition. Additionally, the present invention also relates to use of the FGFR-Fc fusion protein in the preparation of medicaments for the treatment or prevention of angiogenesis-related diseases. Preferably, angiogenesis-related diseases are tumors or ophthalmic angiogenesis-related disease.

[0150] Angiogenesis-related diseases include, but are not limited to, angiogenesis-dependent cancers, including, for example, solid tumors, hematogenic tumors (for example leukemia) and tumor metastasis; benign tumors, for example, angioma, acoustic neuroma, neurofibroma, trachoma and pyogenic granuloma; rheumatoid arthritis; psoriasis; rubeosis; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joint and angiofibroma.

[0151] In some embodiments of the methods described, one or more FGFR-Fc fusion proteins may be administrated together (simultaneously) or at a different time (sequentially). Additionally, the fusion protein may be administrated together with one or more additional medicaments used for cancer treatment or angiogenesis inhibition.

[0152] In some embodiments, the method disclosed in the present invention may be used alone. Alternatively, the subject method may be combined with other conventional anticancer therapies for the treatment or prevention of proliferative diseases (for example tumors). For example, these methods may be used for the prevention of cancers, the prevention of cancer relapse and postoperative metastasis, and may be used as a supplement for other cancer therapies. The effectiveness of conventional cancer therapies (for example, chemotherapy, radiotherapy, phototherapy, immunotherapy and operation) may be enhanced by using target polypeptide therapeutic agents.

[0153] In ophthalmology, angiogenesis is related to, for example, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, corneal transplantation rejection, neovascular glaucoma and RLF (retrolental fibroplasia). The FGFR-Fc fusion protein disclosed herein can be administrated inside the eye or by other routes. Other diseases related to angiogenesis in ophthalmology include, but are not limited to, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sjogren, acne rosacea, phlyctenosis, syphilis, Mycobacteria infection, lipid degeneration, chemical burn, bacterial ulcer, fungal ulcer, Herpes simplex infection, Herpes zoster infection, protozoan infection, Kaposi sarcoma, Mooren ulcer, Terrien's marginal degeneration, mariginal keratolysis, rheumatoid arthritis, systemic lupus, polyarteritis, trauma, Wegeners sarcoidosis, Scleritis, Steven's Johnson disease, periphigoid radial keratotomy and comeal graph rejection, sickle cell anemia, sarcoid, pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme's disease, systemic lupus erythematosis, retinopathy of prematurity, Eales disease, Bechets disease, infection resulting in retinitis or choroiditis, presumed ocular histoplasmosis, Bests disease, myopia, optic pit, Stargarts disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, trauma and post-laser complication. Other diseases include, but not limited to, rubeosis (neovasculariation of the angle) related diseases and diseases induced by abnormal hyperplasia of the fibrous blood vessel or fibrous tissue, including all kinds of proliferative vitreoretinopathy.

Administration

[0154] The fusion protein of the present invention may be administrated alone, but preferably, as a pharmaceutical composition, which usually comprises a suitable pharmaceutical excipient, diluent or carrier selected according to the intended administration route. The fusion protein may be administrated to the patient in need thereof by any suitable route. A precise dosage will be dependent on many factors, including exact properties of the fusion protein.

[0155] Some suitable administration routes include (but are not limited to) oral, rectal, nasal, topical (including buccal and sublingual), subcutaneous, vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intracutaneous, intrathecal and extradural) administration.

[0156] For intravenous injection and injection at the focal site, active ingredients are present in the form of a parenterally-acceptable aqueous solution, which is free of pyrogen and has appropriate pH value, isotonicity and stability.

[0157] A suitable solution may be well formulated by the skilled one in the art using, for example, isotonic excipients such as sodium chloride injection, Ringer's injection, Ringer's lactate injection. As required, preservative, stabilizer, buffering agent, antioxidant and/or some other additives may be added. The pharmaceutical composition orally administrated may be in a form of tablet, capsule, powder or oral liquid etc. Solid carrier, such as gelatin or adjuvant, may be comprised in a tablet. Liquid pharmaceutical composition usually comprises liquid carrier, such as water, petroleum, animal or vegetable oil, mineral oil or synthetic oil. Also included may be normal saline solution, glucose or other sugar solutions or glycols such as ethylene glycol, propylene glycol or polyethylene glycol.

[0158] Examples of the techniques and schemes as mentioned above and other techniques and schemes as used according to the present invention may be found in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A. (ed), 1980.

Cloning of the Fusion Protein and Construction of the Expression Plasmid

[0159] The FGF receptor fragment can be obtained from the amplification of a cDNA template of a corresponding receptor through PCR. The IgG1 Fc fragment can be obtained from the cDNA amplification of the human-derived IgG1 through PCR. When PCR primers are designed, linking sequences are introduced between different fragments so that these different fragments may be finally linked by overlap PCR to form reading frames for different fusion proteins, and endonuclease BspE I and Pst I sites can be added to both ends of the cDNA. The cDNAs for different fusion proteins may be cloned to the expression plasmid after digestion by BspE I and Pst I. The plasmid after cloning may be determined by endonuclease digestion, electrophoresis and finally DNA sequencing.

Expression and Purification of the Fusion Protein

[0160] The present fusion protein may be expressed and purified by techniques commonly used in the art. DNA from corresponding fusion protein plasmid was purified using plasmid purification kit (MAX) available from Qiagen, and the concentration of plasmid DNA can be determined using UV spectrophotometry, and the plasmid was transfected to CHO cell using FUGENE 6 liposome (Roche). Specific methods for transfection can be performed according to the specification of the product.

[0161] Based on the expression amount required for the proteins, two methods were employed in the present invention for protein expression: (1) transient expression, in which the fusion protein contained culture supernatant was usually harvested 48-72 h after transfection, and the relative content of the fusion protein was then determined using human IgG ELISA so that the fusion protein may be rapidly and efficiently obtained; (2) establishing a stable cell line and producing the common DHFR-defective CHO cell expression system using the recombinant protein medicament expression, the basic process of which includes cell transfection, selection of stably transfected cell, clone screening, stress amplification, culture medium and process optimization etc., and finally realizing a large-scale suspension culture of CHO engineering cell strain in a serum free culture medium. The culture product was collected and the fusion protein was purified using Protein A affinity column. The purified protein was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and subsequently all eluates in which the required expression product was contained were combined and filtered using a 0.22 .mu.m filter, and then protein quantification was carried out according to a plurality of methods such as Lowry protein assay. The volume of CHO cell culture in the present invention was at a level of 10 L bioreactor, through which the fusion protein obtained after purification could satisfy the protein amount required in the animal experiments, and also a basis was established for future scaling-up.

Neutralization of FGF by the Fusion Protein was Validated at a Level of Protein

[0162] After the fusion protein expressed by CHO was obtained, the binding capacity of the fusion protein to FGF is evaluated in the present invention at a level of protein. Binding experiment and affinity experiment were performed for validation in the present invention, in which steps of the binding experiment included: after initially coated by FGF-2 on a 96-well ELISA plate, the coated well was blocked by BSA followed by adding each fusion protein at the same concentration, and then a secondary antibody to human IgG Fc-HRP was added after washing, and the samples were developed, stopped and read at 450 nm on a ELISA plate, and finally the fusion protein which had binding capacity to FGF-2 was screened based on the signal strength. The affinity experiment was performed in order to determine the affinity of the fusion protein to FGF-2 in the solution system, which comprised the following steps: FGF-2 was initially coated on a 96-well ELISA plate to capture the antibody, and then the coated well was blocked by BSA, and subsequently a mixture of the fusion protein and FGF-2 which was previously prepared and incubated were added with a gradient of diluted standards, and after incubation, an HRP-labeled detection antibody was added (using antibody 2 which specifically detected free VEGF or FGF-2), and subsequently the samples were developed, stopped and read at 450 nm on a ELISA plate, and finally the relative concentration of free FGF-2 was detected in the mixture of the fusion protein and FGF-2. Through the experiments above, the fusion protein having a blocking effect on FGF-2 was screened.

Neutralization of FGF by the Fusion Protein was Validated at a Cellular Level

[0163] After the binding capacity of the fusion protein to FGF-2 was determined at a level of protein, its angiogenesis-inhibiting effect will be further validated at a cellular level in the present invention. The inhibition capacity of the fusion protein on the division and migration of the vascular endotheliocyte is examined by the division test using human umbilical vein endothelial cell (HUVEC) and the HUEVC cell migration test. The inhibition capacity of the fusion protein on the division of HUVEC cell can be examined by the HUVEC cell division test, which comprises the following steps during the experiment: 3000 HUVEC cells/well were inoculated to a 96-well plate and cultured at 37.degree. C. in an incubator supplemented with 5% CO.sub.2, and then FGF-2 as well as a mixture of the fusion protein at different concentrations with FGF-2 are added respectively, and after culturing for another 3-4 days, 10% CCK-8 is added and cultured for 2 h before the sample is read at 450 nm on a ELISA plate. The inhibition capacity of the fusion protein on the division of vascular endotheliocyte induced by FGF-2 was evaluated based on the difference of absorbance, and the median effective concentration of the fusion protein was obtained for FGF-2 inhibition. The inhibition capacity of the fusion protein on HUVEC cell migration was examined by the HUVEC cell migration test, which comprises the following steps during the experiment: 50000 HUVEC cells as well as the fusion protein at various concentrations were initially inoculated in the upper chamber, while 600 .mu.L FGF-2 containing culture liquid was added into the lower chamber, and subsequently, the sample was cultured at 37.degree. C. in an incubator supplemented with 5% CO.sub.2 for 20-24 h before cells on the face side of the membrane of the upper chamber were removed, and then cells on the back side of the membrane were fixed, stained and washed with PBS before observed and counted under an inverted microscope. The migration of HUVEC cells induced by the stimulation of FGF-2 was demonstrated by counting the HUVEC cells on the back side of the membrane, and the inhibition capacity of the fusion protein on the migration of the vascular endotheliocyte was tested by adding the fusion protein at various concentrations into the culture liquid. Through the experiments mentioned above, the inhibition capacity of the new fusion protein constructed in the present invention was validated on the division and migration of the vascular endotheliocyte induced by FGF-2, which also provided a basis for future animal experiments.

Tumor Growth-Inhibiting Capacity of the Fusion Protein was Validated by the Tumor Model

[0164] After the blocking effect of the new fusion protein in the present invention on FGF-2 signal was demonstrated by experiments at a protein level and a cellular level, its anti-tumor capacity would be tested in animal tumor models in the present invention. In the present invention, the anti-angiogenesis and anti-tumor effect of the fusion protein would be validated by models commonly used in searching medicaments for angiogenesis and tumor, for example, LLC mouse lung cancer, U87 gliocytoma, B16 melanoma and so on. In animal experiments, in addition to conventional control groups, control medicaments, such as VEGF-Trap, FP-1039, would also be included so as to obtain comparative data for anti-tumor capacity. During experiments, 100 .mu.L tumor cell liquid with appropriate amount was subcutaneously injected into C57 mouse on one side of the back, and the tumor volume was measured with a vernier caliper twice a week. Upon the tumor grew to about 200 mm.sup.3, the fusion protein at various concentrations was subcutaneously injected and the mice were sacrificed after 2-3 weeks. Subsequently, the tumor volume was measured with a vernier caliper, and the anti-tumor effect of the fusion protein was validated by the size of the tumor. Furthermore, individual tumor tissue was analyzed using methods such as immunohistochemistry to investigate the regulation mechanism of angiogenesis.

EXAMPLES

Example 1

Construction of Recombinant Expression Plasmid for FGFR1-Fc Fusion Protein

[0165] The FGF receptor fragment is obtained from the amplification of the cDNA templet of FGF receptor through PCR, and IgG1 Fe fragment is obtained from the cDNA amplification of the human-derived IgG1 through PCR. A commercially available cDNA (PCR Ready First Strand cDNA, derived from human adult colon cancer tissue, BioChain) was used as the template for FGFR1 fragment. Total RNA was extracted from the blood of healthy human subjects using human blood RNA extraction kit (QIAGEN). According to the manufacturer's instruction of reverse transcription kit (Promega), RT-PCR was performed using M-MLV reverse transcriptase (Promega) so that RNA was reversely transcripted to cDNA which was used as the template for IgG1 Fc fragment. RT-PCR was performed according to the manufacturer's instruction of reverse transcription kit, which has the following steps: Oligo dT, dNTP, total RNA and DEPC H.sub.2O were mixed homogeneously and reacted at 70.degree. C. for 10 min before placed on ice for 5 min, and subsequently RNase inhibitor, M-MLV reverse transcriptase and reaction buffer were added. The mixture was reacted at 42.degree. C. for 1 h and subsequently at 70.degree. C. for 15 min, and the cDNA obtained may be used as the template.

[0166] Various FGFR1 fragments were individually amplified by PCR using the cDNA from human adult colon cancer tissue as the template (the primers were listed in table 1), and IgG1 Fc fragment was amplified by PCR using human blood cDNA as the template (the primers were listed in table 1 and 2). The reaction conditions for the PCR were as follows: 5 min of pre-denaturalization at 98.degree. C., total 30 cycles of 30 s of denaturalization at 98.degree. C., 45 s of annealing at 56.degree. C. and 2 min of extension at 72.degree. C., and finally another 10 min of extension. When PCR primers were designed, 20 or more complementary base sequences were introduced as the linking sequence between FGFR1 fragment and IgG1 Fc fragment so that the FGFR1 fragment and IgG1 Fc fragment may be subsequently linked by overlap PCR to form reading frames for different fusion proteins, and at the same time, restriction endonuclease BspE I and Pst I site were added at both ends of the PCR product.

[0167] Subsequently, overlap PCR was carried out to obtain each FGFR1-Fc fusion protein fragment by amplification. The process of the overlap PCR reaction may be divided into two rounds, in which the fragment required for linking and containing no primer was included in the first round with reaction conditions as follows: 5 min of pre-denaturalization at 98.degree. C., 6 cycles of 30 s of denaturalization at 98.degree. C., 45 s of annealing at 56.degree. C. and 5 min of extension at 72.degree. C., and finally another 10 min of extension at 72.degree. C.; after the first round, the second round of PCR was carried out by adding the primers for both ends with reaction conditions as follows: 5 min of pre-denaturalization at 98.degree. C., 30 cycles of 30 s of denaturalization at 98.degree. C., 45 s of annealing at 56.degree. C. and 2 min of extension at 72.degree. C., and finally another 10 min of extension at 72.degree. C.; through the process above, reading frames for different fusion proteins were spliced, and at the same time, restriction endonuclease BspE I and Pst I site were added at both ends of the cDNA.

[0168] After amplification, the fragments amplified by PCR were purified using QIAquick PCR purification kit (QIAGEN). cDNAs of various fusion proteins and the eucaryotic expression plasmid pSV2-dhfr (ATCC) were digested by BspE I and Pst I, respectively. Subsequently, 1% agarose gel electrophoresis was performed on the digested samples under a voltage of 90 V. Target fragments were recovered using QIAquick gel extraction kit (QIAGEN) before ligating at 16.degree. C. for 1 h using a ligase (NEB). The mixture for ligation reaction was transformed to the competent Top 10 E. coli under the conditions of 90 s of reaction at 42.degree. C. followed by 3 min of standing on ice. After the sterile LB culture broth (free of antibody) added, the mixture was shaken at 250 rpm in a shaker at 37.degree. C. for 1 h before coating on a LB plate supplemented with ampicillin. The plate was cultured overnight in a thermostated incubator at 37.degree. C., and then single colonies were picked out and transferred to an ampicillin-containing LB culture broth. The inoculated culture broth was shaken at 250 rpm in a shaker at 37.degree. C. overnight before the plasmid was extracted using alkaline lysis. Subsequently, the sample was digested by restriction endonuclease before evaluated by 1% agarose gel electrophoresis under a voltage of 90 V. The recombinant plasmid with correct endonuclease digestion was confirmed by DNA sequencing. Based on the steps above, 19#, 13#, 22#, 23#, 26#, 29# and 8# expression plasmid for FGFR1-Fc fusion protein were constructed. The protein sequence of FGFR1-Fc in each fusion protein and its encoding nucleotide sequence were listed in Table 3. The schematic diagram of the fusion protein structure was shown in FIG. 1.

TABLE-US-00002 TABLE 1 Primers used for amplification of FGFR1 fragment Fusion protein Upstream primer Downstream primer 19# 19#-FGFR1For (SEQ ID NO: 24) FGFR1Rev ( SEQ ID NO: 31) TAGTTCCGGAAGGCCGTCCCCGACCTTGCCTG GTTTTGTCCTCCAGGTACA GGGGCGAGGTC 13# 13#-FGFR1For (SEQ ID NO: 25) FGFR1Rev TAGTTCCGGAAAAAATCGCACCCGCATCACAG 22# 22#-FGFR1For (SEQ ID NO: 26) FGFR1Rev TAGTTCCGGAGTAACCAGCAGCCCCTCGGGC 23# 23#-FGFR1For (SEQ ID NO: 27) FGFR1Rev TAGTTCCGGATCCTCTTCAGAGGAGAAAGAAAC 26# 26#-FGFR1For (SEQ ID NO: 28) FGFR1Rev TAGTTCCGGAAAACCTAACCCCGTAGCTCCAT 29# 29#-FGFR1For (SEQ ID NO: 29) FGFR1Rev TAGTTCCGGACCATATTGGACATCCCCAGAAAAG 8# 8#-FGFR1For (SEQ ID NO: 30) FGFR1Rev CTAGCTCCGGACCAGAAAAGATGGAAAAGAAATT GC

TABLE-US-00003 TABLE 2 Primers used for amplification of IgG1 Fc fragment Downstream Upstream primer primer IgG1 FcFor (SEQ ID NO: 32) FcRev Fc CTGTACCTGGAGGACAAAACTCACACATGC (SEQ ID NO: 33) frag- GATATCTGCAGTCAT ment TTACCCGGAGACAGG

TABLE-US-00004 TABLE 3 Protein sequences and nucleotide sequences for FGFR1-Fc fusion proteins Fusion protein Protein Sequence Nucleotide Sequence 19# SEQ ID NO: 9 SEQ ID NO: 16 13# SEQ ID NO: 10 SEQ ID NO: 17 22# SEQ ID NO: 11 SEQ ID NO: 18 23# SEQ ID NO: 12 SEQ ID NO: 19 26# SEQ ID NO: 13 SEQ ID NO: 20 29# SEQ ID NO: 14 SEQ ID NO: 21 8# SEQ ID NO: 15 SEQ ID NO: 22

Example 2

Transient Expression and Quantification of the Fusion Proteins

[0169] The DNA of individual fusion protein plasmid was purified using MAX Plasmid Purification Kit (Qiagen). The concentration of the plasmid DNA was determined by UV spectrophotometry. 1 .mu.g recombinant plasmid and 6 .mu.L liposome (FuGENE 6 Transfection Reagent, Roche) were homogeneously mixed into 100 .mu.L fresh IMDM culture broth (GIBCO); after standing for 15 min, the mixture was added to the CHO cells (ATCC) cultured overnight after inoculation at a cell density of 3.times.10.sup.5/mL into a 6-well plate; the mixture was cultured at 37.degree. C. in an incubator supplemented with 5% CO.sub.2 for 48 h with a cell complete culture broth (IMDM medium containing 10% FBS, 1% HT and 1% glutamine, all supplied by GIBCO); subsequently, the supernatant was collected and determined for the relative content of the fusion protein using human IgG ELISA kit for protein quantification (BETHYL). The relative content of the fusion protein expressed and secreted by CHO was determined with the following steps: 100 .mu.L anti-human IgG-Fc protein (10 .mu.g/mL) purified by affinity was coated to a 96-well ELISA plate (IMMULON) and subsequently washed for 5 times using 300 .mu.L PBST washing solution; each coated well was blocked with 200 .mu.L freshly prepared blocking working solution (blocking stock solution: PBS=1:19) and incubated at 37.degree. C. for 1 h; after washed in 300 .mu.L PBST washing solution for 5 times, 100 .mu.L IgG solution diluted in a gradient (200 ng/mL original concentration and diluted by PBS in the multiple proportion of 1:2) as a standard and 100 .mu.L culture supernatant of each fusion protein diluted in a gradient (starting with the concentration of each culture supernatant, and diluted by PBS in the multiple proportion of 1:5) were added to each well and incubated at 37.degree. C. for 2 h; after washed in 300 .mu.L PBST washing solution for 5 times, 100 .mu.L anti-human IgG Fc-HRP secondary antibodies diluted with PBS in a ratio of 1:10000 was added and incubated at 37.degree. C. for 1 h; after washed, the well was developed by adding 100 .mu.L developing solution (KPL); finally, after the development was stopped by adding 100 .mu.L stopping solution (KPL), the absorbance of the ELISA plate was read at a wavelength of 450 nm on a ELISA reader. The concentrations of various fusion proteins may thereby be determined according to the standard curve.

Example 3

Binding of the Fusion Proteins

[0170] The binding capacity of 19#, 13#, 22#, 23#, 26#, 29# and 8# fusion protein constructed above to FGF-2 was detected by ELISA.

[0171] Initially, a 96-well ELISA plate (IMMULON Company) was coated by 100 .mu.l solution containing 50 ng/mL FGF-2 (R&D Systems) as well as containing 100 ng/mL heparin (Sigma Company) and 50 ng/mL FGF-2. Subsequently, the plate was washed by 300 .mu.L PBST washing solution for 5 times before each coated well was blocked by 200 .mu.L freshly prepared blocking working solution (KPL Company) (blocking stock solution: PBS=1:19) and incubated at 37.degree. C. for 1 h. After washed in 300 .mu.L PBST washing solution for 5 times, 100 .mu.L solutions of various fusion proteins (dissolve in PBS, pH=7.2, concentration of 20 ng/ml) were added and incubated at 37.degree. C. for 2 h. After washed in 300 .mu.L PBST washing solution for 5 times, 100 .mu.L secondary antibody to human IgG Fc-HRP (BETHYL Company) diluted with PBS in a ratio of 1:10000 was added and incubated at 37.degree. C. for 1 h. After washing in 300 .mu.L PBST washing solution 5 times, the well was developed to the presence of color at room temperature in a dark place by adding 100 .mu.L developing solution (KPL Company), and finally the development was stopped by adding 100 .mu.L, stopping solution (KPL Company) before the absorbance of the ELISA plate was read at a wavelength of 450 nm on a ELISA reader.

[0172] The higher the binding capacity of the fusion protein to FGF2, the larger the absorbance and the stronger the signal. Based on the strength of the signal, 26# fusion protein was determined to have the highest binding capacity to FGF-2.

[0173] Comparison of FGF-2 binding among various fusion proteins is shown in FIG. 2. It can be seen from FIG. 2 that 19#, 13#, 22#, 23#, 26# and 29# fusion protein bound to FGF at different extents in the presence of heparin, and particularly, the binding extent of 23#, 26# and 29# was extremely higher than control, and higher than that of 19#, 13# and 22#, indicating that the fusion proteins containing no acidic box had excellent effect.

[0174] Among others, especially high binding extent was demonstrated by 26#, indicating that the fusion protein had significantly better binding effect when it comprises a part of certain length derived from the intermediate functional sequence of the Ig-like domain of FGFR.

Example 4

Stable Expression and Purification of the Fusion Proteins

[0175] DHFR-defective CHO cells (ATCC) were transfected by the recombinant expression plasmid of 26# fusion protein (possessing a high FGF-2 binding capacity) through a liposome (Roche).

[0176] Particularly, 5 .mu.g recombinant plasmid and 30 .mu.L liposome (FuGENE 6 Transfection Reagent, Roche) were homogeneously mixed into 100 .mu.L fresh IMDM culture broth (GIBCO); after standing for 15 min, the mixture was added to the DHFR-defective CHO cells (ATCC) cultured overnight after inoculation at a cell density of 3.times.10.sup.5/mL in a 10 cm culture dish (Corning); the mixture was cultured at 37.degree. C. in an incubator supplemented with 5% CO.sub.2 for 2-3 days with a cell complete culture broth containing 10% FBS, 1% HT and 1% glutamine in a IMDM culture medium (all supplied by GIBCO); subsequently, the cells were digested by trypsin (GIBCO), inoculated at a cell density of 3.times.10.sup.5/mL in 30 mL serum-free 302 culture medium (SAFC) in a flask, and selectively cultured at 37.degree. C. in an incubator supplemented with 5% CO.sub.2 at 100 rpm to a cell density of 10.sup.6/mL.

[0177] Subsequently, 3000 cells were inoculated into a 10 cm culture dish (Corning) (the culture broth containing 10% FBS and 1% glutamine in an IMDM culture medium) and cultured at 37.degree. C. in an incubator supplemented with 5% CO.sub.2 to form single clones.

[0178] These single clones were picked out and cultured in a 96-well plate (Corning). The relative content of the fusion protein expressed and secreted by each individual single clone was determined using a human IgG ELISA kit for protein quantification (BETHYL) under the same conditions and steps as described in Example 2 for the determination of the relative content of the fusion protein. The clone with the highest expression amount was screened out and transferred to a 6-well plate for culturing to a confluence rate of about 70%. The cells were digested by trypsin and transferred to a 10 cm culture dish. Subsequently, gradual stress amplification was carried out by adding methotrexate (MTX, Sigma) with various concentrations (10 nM, 20 nM, 50 nM, 100 nM, 200 nM and 500 nM). After stress amplification, the cells were digested by trypsin and inoculated at a cell density of 3.times.10.sup.5/mL in a flask. The expression amount of a single cell was determined so that genetically engineered stains of CHO were obtained for expressing a particular fusion protein. Finally, large-scale suspension culture (volume of 10 L) of the genetically engineered stain of CHO was carried out at 37.degree. C., 5% CO.sub.2, 40% dissolved oxygen and 80 rpm in a serum-free 302 culture medium (pH 7.0, SAFC). The culture product was collected by centrifugation. After the supernatant was filtered using 0.45 .mu.m filter membrane (Millipore), affinity chromatography was performed according to the instruction manual of Protein A affinity column (GE) with the specific steps as follows: initially, a protein A affinity column was equilibrated by a PBS buffer (pH 7.0); subsequently, the supernatant was loaded on the column and washed again with the PBS buffer; finally, the column was eluted with a citric acid buffer (pH 3.0), and the eluent was collected and filtered by a 0.45 .mu.m filter membrane. After virus inactivation by adding S/D (0.3% tributyl phosphate/1% Tween 80) at 24.degree. C. for 6 h, the target protein was further purified by a molecular sieve chromatography with the following steps: first, the eluent obtained from the Protein A affinity chromatography was dialyzed in a dialysis bag against a PBS buffer; subsequently, the sample was concentrated in a 10 KD ultrafiltration cup (Millipore); the sample concentrated using the ultrafiltration cup was then loaded on a molecular sieve chromatography column Superdex 200 (GE) equilibrated by a PBS buffer, and subsequently the column was eluted with a PBS buffer and the eluting peak was collected. The purified protein was analyzed by SDS-PAGE (FIG. 3); and subsequently, the eluates containing the required expression product was combined and filtered with a 0.22 .mu.m filter membrane (Millipore) before the protein content was determined using many methods such Lowry protein assay.

Example 5

Gradient-Binding Experiment of the Fusion Proteins

[0179] The binding capacities of the fusion proteins as constructed above to FGF-2 were detected by ELISA, similarly as in Example 3.

[0180] Initially, a 96-well ELISA plate was coated by 100 .mu.L solution containing 50 ng/mL FGF-2 (R&D Systems). Subsequently, the plate was washed in 300 .mu.L PBST washing solution for 5 times before each coated well was blocked by 200 .mu.L freshly prepared blocking working solution (KPL) (blocking stock solution: PBS=1:19) and incubated at 37.degree. C. for 1 h. After washed in 300 .mu.L PBST washing solution for 5 times, 100 .mu.L solutions containing various fusion proteins at different concentrations (the starting content of protein was 16000 pM, and was diluted in a ratio of 1:3) were added and incubated at 37.degree. C. for 2 h. After washed in 300 .mu.L PBST washing solution for 5 times, 100 .mu.L anti-human IgG Fc-HRP secondary antibody (BETHYL) diluted with PBS in a ratio of 1:10000 was added and incubated at 37.degree. C. for 1 h. After washed in 300 .mu.L PBST washing solution for 5 times, the well was developed by adding 100 .mu.L developing solution (KPL), and finally the development was stopped by adding 100 .mu.L stopping solution (KPL) before the absorbance of the ELISA plate was read at a wavelength of 450 nm on a ELISA reader. Based on the intensity of the signal, the gradient binding capacities of the fusion proteins to FGF-2 were determined. In the experiment procedure mentioned above, specific conditions and steps may be found in Example 3. Gradient binding of 26# fusion protein to FGF-2 was compared in FIG. 4. It can be seen that the binding capacity of 26# fusion protein to FGF-2 was dose-dependent.

[0181] It has been suggested by this example that the binding capacity to FGF-2 increased with an enhanced molar concentration of 26# fusion protein, manifested by a stronger signal at a wavelength of 450 nm; while the binding capacity to FGF-2 decreased correspondingly with a gradient dilution of the molar concentration of 26# fusion protein.

Example 6

Affinity Experiment of the Fusion Proteins

[0182] The affinity of the fusion protein to FGF-2 in a solution system was determined by an affinity experiment.

[0183] Initially, a 96-well ELISA plate was coated by 100 .mu.L solution containing 2.0 .mu.g/mL FGF-2 capture antibody (R&D Systems). Subsequently, the plate was washed in 300 .mu.L PBST washing solution for 5 times before each coated well was blocked by a blocking working solution (KPL) (as seen in Example 3) and incubated at 37.degree. C. for 1 h. After washed in 300 .mu.L PBST washing solution for 5 times, previously prepared and incubated (4.degree. C. overnight) mixture of the fusion proteins and FGF-2 as well as the standard (R&D Systems) diluted in a gradient were added, in which the specific preparation procedure was as follows: the starting concentration of 26# fusion protein was 400 pM (dissolved in PBS) and diluted in a gradient ratio of 2-fold, and the solutions of the fusion protein were 1:1 mixed with 20 pM FGF-2 solution (dissolved in PBS), and that is, the starting final concentration of each fusion protein was 200 pM, and the final concentration of FGF-2 was 10 pM in the mixture solution prepared. The plate was incubated at 37.degree. C. for 2 h and washed in 300 .mu.L PBST washing solution for 5 times before 100 .mu.L FGF-2 detection antibody solution (250 ng/mL) was added (R&D systems, which may specifically detect free antibodies against FGF-2). The plate was incubated at 37.degree. C. for 2 h and washed in 300 .mu.L PBST washing solution for 5 times, and subsequently, HRP labeled streptavidin (R&D systems) was added (diluted by PBS in 1:200). The plate was incubated at 37.degree. C. for 2 h and washed in 300 .mu.L PBST washing solution for 5 times before the well was developed at room temperature in a dark place for an appropriate duration (about 15-30 min) by adding 100 .mu.L developing solution (KPL). Finally, after the development was stopped by adding 100 .mu.L stopping solution (KPL), the absorbance of the ELISA plate was read at a wavelength of 450 nm on a ELISA reader. The relative concentration of free FGF-2 in the mixture of the fusion protein and FGF-2 was determined. The affinity between 26# fusion protein and FGF-2 in a solution system can be seen in FIG. 5. As demonstrated in this Example, 26# fusion protein had high affinity to FGF-2 in a solution system. The affinity increased with an enhanced concentration, which is manifested as a decreased amount of free FGF-2 with an enhanced concentration of the fusion protein. The affinity between 26# fusion protein and FGF-2 in a solution system can be seen in FIG. 5. As demonstrated in this Example, 26# fusion protein had affinity to FGF-2 in a solution system. The affinity increased with an enhanced concentration, which is manifested as a decreased amount of free FGF-2.

Example 7

Inhibitory Test for Division on Human Umbilical Vein Endothelial Cell

[0184] The inhibitory ability of the fusion proteins on the division of vascular endothelial cells was examined in a division test for human umbilical vein endothelial cell (HUVEC).

[0185] HUVEC cells (AllCells) were cultured to the exponential growth phase in an HUVEC complete medium (AllCells) at 37.degree. C. in an incubator supplemented with 5% CO.sub.2. HUVEC cells were counted after digested by trypsin. 3000 HUVEC cells were inoculated per well in an HUVEC basal medium containing 1% FBS (AllCells) in a 96-well plate. The plate was cultured overnight at 37.degree. C. in an incubator supplemented with 5% CO.sub.2.

[0186] 100 .mu.L FGF-2 (R&D Systems) solution (final concentration of 5 ng/mL) diluted by an HUVEC basal medium containing 1% FBS, as well as 100 .mu.L mixture of various amount of 26# fusion protein and FGF-2 (in which the final concentration of the fusion protein was 40 pM, diluted in an HUVEC basal medium containing 1% FBS with a ratio of 1:10, and the final concentration of FGF-2 was 5 ng/mL) were added and cultured for another 3-4 days. Subsequently, the culture medium was taken out and a culture medium containing 10% CCK-8 (DOJINDO) was added for another 2 h of culture before the absorbance of the 96-well plate was read directly at a wavelength of 450 nm on an ELISA reader. Based on the difference of the absorbance, the inhibitory ability of the fusion protein on the division of vascular endothelial cells induced by FGF-2 was determined. The effect of the fusion protein on HUVEC cell division induced by FGF-2 was shown in FIG. 6. As demonstrated in this Example, 26# fusion protein has biological activity and function at the cellular level, which can inhibit HUVEC cell division induced by FGF-2, and has the binding capacity to FGF-2. Such binding capacity increases as the molar concentration of 26# fusion protein increases, which is indicated by the inhibition of HUVEC cell division induced by FGF-2.

Example 8

Anti-Tumor Efficacy of FGFR-Fc in Renal Carcinoma Model

[0187] Human renal carcinoma cell line Caki-1 cells (2.times.10.sup.6 cells/mouse) and human lung carcinoma cell line A549 cells (5.times.10.sup.6 cells/mouse) were suspended in serum-free medium and s.c. injected into the right flanks of 6 to 8 weeks old female, athymic BALB/c nu/nu mice. Tumor volume was calculated twice a week with a caliper by the formula of [(length.times.width.times.width)/2]. When tumor size reached around 50.about.100 mm.sup.3, animals were randomized into four groups and received a s.c. injection of FGFR-Fc (#26 fusion protein) at a dose of 25, 2.5, 0.25 mg/kg and PBS twice weekly for 6 to 8 weeks. 3 days after the last dose, animals were sacrificed and tumors were measured. The results are shown in FIG. 7.

Example 9

Anti-Tumor Efficacy of FGFR-Fc in Lung Carcinoma Model

[0188] Effect of FGFR-Fc (#26 fusion protein) on Caki-1 and A549 tumor growth in vivo. Caki-1 cells (2.times.10.sup.6; A) and A549 cells (5.times.10.sup.6; B) were s.c. injected into BALB/c nu/nu mice. FGFR-Fc blocked the growth of indicated s.c. implanted tumors, at the indicated doses twice weekly for 6 to 8 weeks. The tumor volumes [(length.times.width.times.width)/2] were measured, error bars represent standard error of mean, n=6-8 mice/treatment group. The results are shown in FIG. 8.

[0189] The present invention has been illustrated by specific examples. However, it will be appreciated by a person of ordinary skill in the art that the present invention is not limited to the specific embodiments. Various changes and modifications may be made by a person of ordinary skill under the scope of the present invention, and each technical feature mentioned in the specification may be combined without departing from the spirit and scope of the invention. Such changes and modifications fall within the scope of the present invention.

[0190] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

[0191] It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.

REFERENCES

[0192] [1] Hanahan D, Weinberg R A. The hallmarks of cancer. Cell, 2000, 100(1):57-70.

[0193] [2] Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86:353-64.

[0194] [3] Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003, 9:669-76.

[0195] [4] Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004, 1:2-10.

[0196] [5] Jenab-Wolcott J, Giantonio B J. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther. 2009, 9(4):507-17.

[0197] [6] Summers J, Cohen M H, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist. 2010, 15(1):104-11.

[0198] [7] Hsu J Y, Wakelee H A. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. 2009, 23(5):289-304.

[0199] [8] Krupitskaya Y, Wakelee H A. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs. 2009, 10(6):597-605.

[0200] [9] Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350(23):2335-42.

[0201] [10] Sandler A, Gray R, Perry M C, Brahmer J, Schiller J H, Dowlati A, Lilenbaum R, Johnson D H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355(24):2542-50.

[0202] [11] Jenab-Wolcott J, Giantonio B J. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther, 2009, 9(4):507-17.

[0203] [12] Dorrell M I, Aguilar E, Scheppke L, Barnett F H, Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA. 2007, 104(3):967-72.

[0204] [13] Casanovas O, Hicklin D J, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005, 8(4):299-309.

[0205] [14] A Beenken, M Mohammadi. Nature Rev., 2009, 8(3): 235.about.53.

[0206] [15] M Mohammadi, S K Olsen, O A Ibrahimi. Cytokine, 2005, 16: 107.about.137.

[0207] [16] M Presta, P D Era, S Mitola et al. Cytokine, 2005, 16(2): 159.about.178.

[0208] [17] R Grose, C Dickson. Cytokine, 2005, 16(2): 179.about.186.

[0209] [18] Y H Cao, R H Cao, E M Hedlund. J. Mol. Med., 2008, 86(7): 785.about.789.

[0210] [19] M J Cross, L C Welsh. Trends Pharmacol. Sci., 2001, 22(4): 201.about.207.

[0211] [20] Wang F. et al., J Biol Chem. 1995, 270:10231-10235

[0212] [21] Olsen S K. et al., Proc Natl Acad Sci USA. 2004, 101:935-940

[0213] [22] Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stattner S. Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B. Hepatology. 2011 March; 53(3):854-64.

Sequence CWU 1

1

331820PRTHomo sapiensMISC_FEATURE(1)..(820)amino acid sequence of human FGFR1 1Met Trp Ser Trp Lys Cys Leu Leu Phe Trp Ala Val Leu Val Thr Ala 1 5 10 15 Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu Pro Glu Gln Ala Gln 20 25 30 Pro Trp Gly Ala Pro Val Glu Val Glu Ser Phe Leu Val His Pro Gly 35 40 45 Asp Leu Leu Gln Leu Arg Cys Arg Leu Arg Asp Asp Val Gln Ser Ile 50 55 60 Asn Trp Leu Arg Asp Gly Val Gln Leu Ala Glu Ser Asn Arg Thr Arg 65 70 75 80 Ile Thr Gly Glu Glu Val Glu Val Gln Asp Ser Val Pro Ala Asp Ser 85 90 95 Gly Leu Tyr Ala Cys Val Thr Ser Ser Pro Ser Gly Ser Asp Thr Thr 100 105 110 Tyr Phe Ser Val Asn Val Ser Asp Ala Leu Pro Ser Ser Glu Asp Asp 115 120 125 Asp Asp Asp Asp Asp Ser Ser Ser Glu Glu Lys Glu Thr Asp Asn Thr 130 135 140 Lys Pro Asn Pro Val Ala Pro Tyr Trp Thr Ser Pro Glu Lys Met Glu 145 150 155 160 Lys Lys Leu His Ala Val Pro Ala Ala Lys Thr Val Lys Phe Lys Cys 165 170 175 Pro Ser Ser Gly Thr Pro Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly 180 185 190 Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly Tyr Lys Val Arg Tyr 195 200 205 Ala Thr Trp Ser Ile Ile Met Asp Ser Val Val Pro Ser Asp Lys Gly 210 215 220 Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr Gly Ser Ile Asn His Thr 225 230 235 240 Tyr Gln Leu Asp Val Val Glu Arg Ser Pro His Arg Pro Ile Leu Gln 245 250 255 Ala Gly Leu Pro Ala Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu 260 265 270 Phe Met Cys Lys Val Tyr Ser Asp Pro Gln Pro His Ile Gln Trp Leu 275 280 285 Lys His Ile Glu Val Asn Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro 290 295 300 Tyr Val Gln Ile Leu Lys Thr Ala Gly Val Asn Thr Thr Asp Lys Glu 305 310 315 320 Met Glu Val Leu His Leu Arg Asn Val Ser Phe Glu Asp Ala Gly Glu 325 330 335 Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Leu Ser His His Ser Ala 340 345 350 Trp Leu Thr Val Leu Glu Ala Leu Glu Glu Arg Pro Ala Val Met Thr 355 360 365 Ser Pro Leu Tyr Leu Glu Ile Ile Ile Tyr Cys Thr Gly Ala Phe Leu 370 375 380 Ile Ser Cys Met Val Gly Ser Val Ile Val Tyr Lys Met Lys Ser Gly 385 390 395 400 Thr Lys Lys Ser Asp Phe His Ser Gln Met Ala Val His Lys Leu Ala 405 410 415 Lys Ser Ile Pro Leu Arg Arg Gln Val Thr Val Ser Ala Asp Ser Ser 420 425 430 Ala Ser Met Asn Ser Gly Val Leu Leu Val Arg Pro Ser Arg Leu Ser 435 440 445 Ser Ser Gly Thr Pro Met Leu Ala Gly Val Ser Glu Tyr Glu Leu Pro 450 455 460 Glu Asp Pro Arg Trp Glu Leu Pro Arg Asp Arg Leu Val Leu Gly Lys 465 470 475 480 Pro Leu Gly Glu Gly Cys Phe Gly Gln Val Val Leu Ala Glu Ala Ile 485 490 495 Gly Leu Asp Lys Asp Lys Pro Asn Arg Val Thr Lys Val Ala Val Lys 500 505 510 Met Leu Lys Ser Asp Ala Thr Glu Lys Asp Leu Ser Asp Leu Ile Ser 515 520 525 Glu Met Glu Met Met Lys Met Ile Gly Lys His Lys Asn Ile Ile Asn 530 535 540 Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro Leu Tyr Val Ile Val Glu 545 550 555 560 Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr Leu Gln Ala Arg Arg Pro 565 570 575 Pro Gly Leu Glu Tyr Cys Tyr Asn Pro Ser His Asn Pro Glu Glu Gln 580 585 590 Leu Ser Ser Lys Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly 595 600 605 Met Glu Tyr Leu Ala Ser Lys Lys Cys Ile His Arg Asp Leu Ala Ala 610 615 620 Arg Asn Val Leu Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe 625 630 635 640 Gly Leu Ala Arg Asp Ile His His Ile Asp Tyr Tyr Lys Lys Thr Thr 645 650 655 Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro Glu Ala Leu Phe Asp 660 665 670 Arg Ile Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu 675 680 685 Trp Glu Ile Phe Thr Leu Gly Gly Ser Pro Tyr Pro Gly Val Pro Val 690 695 700 Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro 705 710 715 720 Ser Asn Cys Thr Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His 725 730 735 Ala Val Pro Ser Gln Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu 740 745 750 Asp Arg Ile Val Ala Leu Thr Ser Asn Gln Glu Tyr Leu Asp Leu Ser 755 760 765 Met Pro Leu Asp Gln Tyr Ser Pro Ser Phe Pro Asp Thr Arg Ser Ser 770 775 780 Thr Cys Ser Ser Gly Glu Asp Ser Val Phe Ser His Glu Pro Leu Pro 785 790 795 800 Glu Glu Pro Cys Leu Pro Arg His Pro Ala Gln Leu Ala Asn Gly Gly 805 810 815 Leu Lys Arg Arg 820 21338PRTHomo sapiensMISC_FEATURE(1)..(1338)amino acid sequence of human VEGFR1 2Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser 1 5 10 15 Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro 20 25 30 Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr 35 40 45 Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro 50 55 60 Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala 65 70 75 80 Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr 85 90 95 Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val 100 105 110 Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile 115 120 125 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 130 135 140 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 145 150 155 160 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 165 170 175 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 180 185 190 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 195 200 205 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 210 215 220 Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val 225 230 235 240 Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr 245 250 255 Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys 260 265 270 Asn Lys Arg Ala Ser Val Arg Arg Arg Ile Asp Gln Ser Asn Ser His 275 280 285 Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys 290 295 300 Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys 305 310 315 320 Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Phe Ile Thr Val 325 330 335 Lys His Arg Lys Gln Gln Val Leu Glu Thr Val Ala Gly Lys Arg Ser 340 345 350 Tyr Arg Leu Ser Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val 355 360 365 Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu 370 375 380 Thr Arg Gly Tyr Ser Leu Ile Ile Lys Asp Val Thr Glu Glu Asp Ala 385 390 395 400 Gly Asn Tyr Thr Ile Leu Leu Ser Ile Lys Gln Ser Asn Val Phe Lys 405 410 415 Asn Leu Thr Ala Thr Leu Ile Val Asn Val Lys Pro Gln Ile Tyr Glu 420 425 430 Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser 435 440 445 Arg Gln Ile Leu Thr Cys Thr Ala Tyr Gly Ile Pro Gln Pro Thr Ile 450 455 460 Lys Trp Phe Trp His Pro Cys Asn His Asn His Ser Glu Ala Arg Cys 465 470 475 480 Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe Ile Leu Asp Ala Asp Ser 485 490 495 Asn Met Gly Asn Arg Ile Glu Ser Ile Thr Gln Arg Met Ala Ile Ile 500 505 510 Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg 515 520 525 Ile Ser Gly Ile Tyr Ile Cys Ile Ala Ser Asn Lys Val Gly Thr Val 530 535 540 Gly Arg Asn Ile Ser Phe Tyr Ile Thr Asp Val Pro Asn Gly Phe His 545 550 555 560 Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser 565 570 575 Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp Ile Leu Leu 580 585 590 Arg Thr Val Asn Asn Arg Thr Met His Tyr Ser Ile Ser Lys Gln Lys 595 600 605 Met Ala Ile Thr Lys Glu His Ser Ile Thr Leu Asn Leu Thr Ile Met 610 615 620 Asn Val Ser Leu Gln Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn 625 630 635 640 Val Tyr Thr Gly Glu Glu Ile Leu Gln Lys Lys Glu Ile Thr Ile Arg 645 650 655 Asp Gln Glu Ala Pro Tyr Leu Leu Arg Asn Leu Ser Asp His Thr Val 660 665 670 Ala Ile Ser Ser Ser Thr Thr Leu Asp Cys His Ala Asn Gly Val Pro 675 680 685 Glu Pro Gln Ile Thr Trp Phe Lys Asn Asn His Lys Ile Gln Gln Glu 690 695 700 Pro Gly Ile Ile Leu Gly Pro Gly Ser Ser Thr Leu Phe Ile Glu Arg 705 710 715 720 Val Thr Glu Glu Asp Glu Gly Val Tyr His Cys Lys Ala Thr Asn Gln 725 730 735 Lys Gly Ser Val Glu Ser Ser Ala Tyr Leu Thr Val Gln Gly Thr Ser 740 745 750 Asp Lys Ser Asn Leu Glu Leu Ile Thr Leu Thr Cys Thr Cys Val Ala 755 760 765 Ala Thr Leu Phe Trp Leu Leu Leu Thr Leu Phe Ile Arg Lys Met Lys 770 775 780 Arg Ser Ser Ser Glu Ile Lys Thr Asp Tyr Leu Ser Ile Ile Met Asp 785 790 795 800 Pro Asp Glu Val Pro Leu Asp Glu Gln Cys Glu Arg Leu Pro Tyr Asp 805 810 815 Ala Ser Lys Trp Glu Phe Ala Arg Glu Arg Leu Lys Leu Gly Lys Ser 820 825 830 Leu Gly Arg Gly Ala Phe Gly Lys Val Val Gln Ala Ser Ala Phe Gly 835 840 845 Ile Lys Lys Ser Pro Thr Cys Arg Thr Val Ala Val Lys Met Leu Lys 850 855 860 Glu Gly Ala Thr Ala Ser Glu Tyr Lys Ala Leu Met Thr Glu Leu Lys 865 870 875 880 Ile Leu Thr His Ile Gly His His Leu Asn Val Val Asn Leu Leu Gly 885 890 895 Ala Cys Thr Lys Gln Gly Gly Pro Leu Met Val Ile Val Glu Tyr Cys 900 905 910 Lys Tyr Gly Asn Leu Ser Asn Tyr Leu Lys Ser Lys Arg Asp Leu Phe 915 920 925 Phe Leu Asn Lys Asp Ala Ala Leu His Met Glu Pro Lys Lys Glu Lys 930 935 940 Met Glu Pro Gly Leu Glu Gln Gly Lys Lys Pro Arg Leu Asp Ser Val 945 950 955 960 Thr Ser Ser Glu Ser Phe Ala Ser Ser Gly Phe Gln Glu Asp Lys Ser 965 970 975 Leu Ser Asp Val Glu Glu Glu Glu Asp Ser Asp Gly Phe Tyr Lys Glu 980 985 990 Pro Ile Thr Met Glu Asp Leu Ile Ser Tyr Ser Phe Gln Val Ala Arg 995 1000 1005 Gly Met Glu Phe Leu Ser Ser Arg Lys Cys Ile His Arg Asp Leu 1010 1015 1020 Ala Ala Arg Asn Ile Leu Leu Ser Glu Asn Asn Val Val Lys Ile 1025 1030 1035 Cys Asp Phe Gly Leu Ala Arg Asp Ile Tyr Lys Asn Pro Asp Tyr 1040 1045 1050 Val Arg Lys Gly Asp Thr Arg Leu Pro Leu Lys Trp Met Ala Pro 1055 1060 1065 Glu Ser Ile Phe Asp Lys Ile Tyr Ser Thr Lys Ser Asp Val Trp 1070 1075 1080 Ser Tyr Gly Val Leu Leu Trp Glu Ile Phe Ser Leu Gly Gly Ser 1085 1090 1095 Pro Tyr Pro Gly Val Gln Met Asp Glu Asp Phe Cys Ser Arg Leu 1100 1105 1110 Arg Glu Gly Met Arg Met Arg Ala Pro Glu Tyr Ser Thr Pro Glu 1115 1120 1125 Ile Tyr Gln Ile Met Leu Asp Cys Trp His Arg Asp Pro Lys Glu 1130 1135 1140 Arg Pro Arg Phe Ala Glu Leu Val Glu Lys Leu Gly Asp Leu Leu 1145 1150 1155 Gln Ala Asn Val Gln Gln Asp Gly Lys Asp Tyr Ile Pro Ile Asn 1160 1165 1170 Ala Ile Leu Thr Gly Asn Ser Gly Phe Thr Tyr Ser Thr Pro Ala 1175 1180 1185 Phe Ser Glu Asp Phe Phe Lys Glu Ser Ile Ser Ala Pro Lys Phe 1190 1195 1200 Asn Ser Gly Ser Ser Asp Asp Val Arg Tyr Val Asn Ala Phe Lys 1205 1210 1215 Phe Met Ser Leu Glu Arg Ile Lys Thr Phe Glu Glu Leu Leu Pro 1220 1225 1230 Asn Ala Thr Ser Met Phe Asp Asp Tyr Gln Gly Asp Ser Ser Thr 1235 1240 1245 Leu Leu Ala Ser Pro Met Leu Lys Arg Phe Thr Trp Thr Asp Ser 1250 1255 1260 Lys Pro Lys Ala Ser Leu Lys Ile Asp Leu Arg Val Thr Ser Lys 1265 1270 1275 Ser Lys Glu Ser Gly Leu Ser Asp Val Ser Arg Pro Ser Phe Cys 1280 1285 1290 His Ser Ser Cys Gly His Val Ser Glu Gly Lys Arg Arg Phe Thr 1295 1300 1305 Tyr Asp His Ala Glu Leu Glu Arg Lys Ile Ala Cys Cys Ser Pro 1310 1315 1320 Pro Pro Asp Tyr Asn Ser Val Val Leu Tyr Ser Thr Pro Pro Ile 1325 1330 1335 3 1356PRTHomo sapiensMISC_FEATURE(1)..(1356)amino acid sequence of human VEGFR2 3Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu 1 5 10 15 Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro 20 25 30 Arg Leu Ser Ile Gln Lys Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr 35 40 45 Leu Gln Ile Thr Cys Arg Gly Gln Arg Asp Leu Asp Trp Leu Trp Pro 50 55 60 Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser 65 70 75 80 Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn 85 90 95 Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg

Glu Thr Asp Leu Ala Ser 100 105 110 Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe Ile Ala Ser 115 120 125 Val Ser Asp Gln His Gly Val Val Tyr Ile Thr Glu Asn Lys Asn Lys 130 135 140 Thr Val Val Ile Pro Cys Leu Gly Ser Ile Ser Asn Leu Asn Val Ser 145 150 155 160 Leu Cys Ala Arg Tyr Pro Glu Lys Arg Phe Val Pro Asp Gly Asn Arg 165 170 175 Ile Ser Trp Asp Ser Lys Lys Gly Phe Thr Ile Pro Ser Tyr Met Ile 180 185 190 Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn Asp Glu Ser 195 200 205 Tyr Gln Ser Ile Met Tyr Ile Val Val Val Val Gly Tyr Arg Ile Tyr 210 215 220 Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu 225 230 235 240 Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile 245 250 255 Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu 260 265 270 Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe 275 280 285 Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu 290 295 300 Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr 305 310 315 320 Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met 325 330 335 Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala 340 345 350 Lys Tyr Leu Gly Tyr Pro Pro Pro Glu Ile Lys Trp Tyr Lys Asn Gly 355 360 365 Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly His Val Leu Thr 370 375 380 Ile Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val Ile Leu 385 390 395 400 Thr Asn Pro Ile Ser Lys Glu Lys Gln Ser His Val Val Ser Leu Val 405 410 415 Val Tyr Val Pro Pro Gln Ile Gly Glu Lys Ser Leu Ile Ser Pro Val 420 425 430 Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val Tyr 435 440 445 Ala Ile Pro Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu 450 455 460 Glu Cys Ala Asn Glu Pro Ser Gln Ala Val Ser Val Thr Asn Pro Tyr 465 470 475 480 Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gln Gly Gly Asn Lys 485 490 495 Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn Lys 500 505 510 Thr Val Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr 515 520 525 Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu Arg Val Ile Ser 530 535 540 Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu Gln Pro Asp Met Gln 545 550 555 560 Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser 565 570 575 Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro 580 585 590 Ile His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp Thr 595 600 605 Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp Ile 610 615 620 Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr 625 630 635 640 Val Cys Leu Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val 645 650 655 Arg Gln Leu Thr Val Leu Glu Arg Val Ala Pro Thr Ile Thr Gly Asn 660 665 670 Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys 675 680 685 Thr Ala Ser Gly Asn Pro Pro Pro Gln Ile Met Trp Phe Lys Asp Asn 690 695 700 Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg 705 710 715 720 Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Leu Tyr Thr 725 730 735 Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe 740 745 750 Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu Ile Ile Ile Leu 755 760 765 Val Gly Thr Ala Val Ile Ala Met Phe Phe Trp Leu Leu Leu Val Ile 770 775 780 Ile Leu Arg Thr Val Lys Arg Ala Asn Gly Gly Glu Leu Lys Thr Gly 785 790 795 800 Tyr Leu Ser Ile Val Met Asp Pro Asp Glu Leu Pro Leu Asp Glu His 805 810 815 Cys Glu Arg Leu Pro Tyr Asp Ala Ser Lys Trp Glu Phe Pro Arg Asp 820 825 830 Arg Leu Lys Leu Gly Lys Pro Leu Gly Arg Gly Ala Phe Gly Gln Val 835 840 845 Ile Glu Ala Asp Ala Phe Gly Ile Asp Lys Thr Ala Thr Cys Arg Thr 850 855 860 Val Ala Val Lys Met Leu Lys Glu Gly Ala Thr His Ser Glu His Arg 865 870 875 880 Ala Leu Met Ser Glu Leu Lys Ile Leu Ile His Ile Gly His His Leu 885 890 895 Asn Val Val Asn Leu Leu Gly Ala Cys Thr Lys Pro Gly Gly Pro Leu 900 905 910 Met Val Ile Val Glu Phe Cys Lys Phe Gly Asn Leu Ser Thr Tyr Leu 915 920 925 Arg Ser Lys Arg Asn Glu Phe Val Pro Tyr Lys Thr Lys Gly Ala Arg 930 935 940 Phe Arg Gln Gly Lys Asp Tyr Val Gly Ala Ile Pro Val Asp Leu Lys 945 950 955 960 Arg Arg Leu Asp Ser Ile Thr Ser Ser Gln Ser Ser Ala Ser Ser Gly 965 970 975 Phe Val Glu Glu Lys Ser Leu Ser Asp Val Glu Glu Glu Glu Ala Pro 980 985 990 Glu Asp Leu Tyr Lys Asp Phe Leu Thr Leu Glu His Leu Ile Cys Tyr 995 1000 1005 Ser Phe Gln Val Ala Lys Gly Met Glu Phe Leu Ala Ser Arg Lys 1010 1015 1020 Cys Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu Ser Glu 1025 1030 1035 Lys Asn Val Val Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile 1040 1045 1050 Tyr Lys Asp Pro Asp Tyr Val Arg Lys Gly Asp Ala Arg Leu Pro 1055 1060 1065 Leu Lys Trp Met Ala Pro Glu Thr Ile Phe Asp Arg Val Tyr Thr 1070 1075 1080 Ile Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile 1085 1090 1095 Phe Ser Leu Gly Ala Ser Pro Tyr Pro Gly Val Lys Ile Asp Glu 1100 1105 1110 Glu Phe Cys Arg Arg Leu Lys Glu Gly Thr Arg Met Arg Ala Pro 1115 1120 1125 Asp Tyr Thr Thr Pro Glu Met Tyr Gln Thr Met Leu Asp Cys Trp 1130 1135 1140 His Gly Glu Pro Ser Gln Arg Pro Thr Phe Ser Glu Leu Val Glu 1145 1150 1155 His Leu Gly Asn Leu Leu Gln Ala Asn Ala Gln Gln Asp Gly Lys 1160 1165 1170 Asp Tyr Ile Val Leu Pro Ile Ser Glu Thr Leu Ser Met Glu Glu 1175 1180 1185 Asp Ser Gly Leu Ser Leu Pro Thr Ser Pro Val Ser Cys Met Glu 1190 1195 1200 Glu Glu Glu Val Cys Asp Pro Lys Phe His Tyr Asp Asn Thr Ala 1205 1210 1215 Gly Ile Ser Gln Tyr Leu Gln Asn Ser Lys Arg Lys Ser Arg Pro 1220 1225 1230 Val Ser Val Lys Thr Phe Glu Asp Ile Pro Leu Glu Glu Pro Glu 1235 1240 1245 Val Lys Val Ile Pro Asp Asp Asn Gln Thr Asp Ser Gly Met Val 1250 1255 1260 Leu Ala Ser Glu Glu Leu Lys Thr Leu Glu Asp Arg Thr Lys Leu 1265 1270 1275 Ser Pro Ser Phe Gly Gly Met Val Pro Ser Lys Ser Arg Glu Ser 1280 1285 1290 Val Ala Ser Glu Gly Ser Asn Gln Thr Ser Gly Tyr Gln Ser Gly 1295 1300 1305 Tyr His Ser Asp Asp Thr Asp Thr Thr Val Tyr Ser Ser Glu Glu 1310 1315 1320 Ala Glu Leu Leu Lys Leu Ile Glu Ile Gly Val Gln Thr Gly Ser 1325 1330 1335 Thr Ala Gln Ile Leu Gln Pro Asp Ser Gly Thr Thr Leu Ser Ser 1340 1345 1350 Pro Pro Val 1355 4 5911DNAHomo sapiensmisc_feature(1)..(5911)nucleotide sequence of human FGFR1 (CDS 943-3405) 4agatgcaggg gcgcaaacgc caaaggagac caggctgtag gaagagaagg gcagagcgcc 60ggacagctcg gcccgctccc cgtcctttgg ggccgcggct ggggaactac aaggcccagc 120aggcagctgc agggggcgga ggcggaggag ggaccagcgc gggtgggagt gagagagcga 180gccctcgcgc cccgccggcg catagcgctc ggagcgctct tgcggccaca ggcgcggcgt 240cctcggcggc gggcggcagc tagcgggagc cgggacgccg gtgcagccgc agcgcgcgga 300ggaacccggg tgtgccggga gctgggcggc cacgtccgga cgggaccgag acccctcgta 360gcgcattgcg gcgacctcgc cttccccggc cgcgagcgcg ccgctgcttg aaaagccgcg 420gaacccaagg acttttctcc ggtccgagct cggggcgccc cgcagggcgc acggtacccg 480tgctgcagtc gggcacgccg cggcgccggg gcctccgcag ggcgatggag cccggtctgc 540aaggaaagtg aggcgccgcc gctgcgttct ggaggagggg ggcacaaggt ctggagaccc 600cgggtggcgg acgggagccc tccccccgcc ccgcctccgg ggcaccagct ccggctccat 660tgttcccgcc cgggctggag gcgccgagca ccgagcgccg ccgggagtcg agcgccggcc 720gcggagctct tgcgaccccg ccaggacccg aacagagccc gggggcggcg ggccggagcc 780ggggacgcgg gcacacgccc gctcgcacaa gccacggcgg actctcccga ggcggaacct 840ccacgccgag cgagggtcag tttgaaaagg aggatcgagc tcactgtgga gtatccatgg 900agatgtggag ccttgtcacc aacctctaac tgcagaactg ggatgtggag ctggaagtgc 960ctcctcttct gggctgtgct ggtcacagcc acactctgca ccgctaggcc gtccccgacc 1020ttgcctgaac aagcccagcc ctggggagcc cctgtggaag tggagtcctt cctggtccac 1080cccggtgacc tgctgcagct tcgctgtcgg ctgcgggacg atgtgcagag catcaactgg 1140ctgcgggacg gggtgcagct ggcggaaagc aaccgcaccc gcatcacagg ggaggaggtg 1200gaggtgcagg actccgtgcc cgcagactcc ggcctctatg cttgcgtaac cagcagcccc 1260tcgggcagtg acaccaccta cttctccgtc aatgtttcag atgctctccc ctcctcggag 1320gatgatgatg atgatgatga ctcctcttca gaggagaaag aaacagataa caccaaacca 1380aaccccgtag ctccatattg gacatcccca gaaaagatgg aaaagaaatt gcatgcagtg 1440ccggctgcca agacagtgaa gttcaaatgc ccttccagtg ggaccccaaa ccccacactg 1500cgctggttga aaaatggcaa agaattcaaa cctgaccaca gaattggagg ctacaaggtc 1560cgttatgcca cctggagcat cataatggac tctgtggtgc cctctgacaa gggcaactac 1620acctgcattg tggagaatga gtacggcagc atcaaccaca cataccagct ggatgtcgtg 1680gagcggtccc ctcaccggcc catcctgcaa gcagggttgc ccgccaacaa aacagtggcc 1740ctgggtagca acgtggagtt catgtgtaag gtgtacagtg acccgcagcc gcacatccag 1800tggctaaagc acatcgaggt gaatgggagc aagattggcc cagacaacct gccttatgtc 1860cagatcttga agactgctgg agttaatacc accgacaaag agatggaggt gcttcactta 1920agaaatgtct cctttgagga cgcaggggag tatacgtgct tggcgggtaa ctctatcgga 1980ctctcccatc actctgcatg gttgaccgtt ctggaagccc tggaagagag gccggcagtg 2040atgacctcgc ccctgtacct ggagatcatc atctattgca caggggcctt cctcatctcc 2100tgcatggtgg ggtcggtcat cgtctacaag atgaagagtg gtaccaagaa gagtgacttc 2160cacagccaga tggctgtgca caagctggcc aagagcatcc ctctgcgcag acaggtaaca 2220gtgtctgctg actccagtgc atccatgaac tctggggttc ttctggttcg gccatcacgg 2280ctctcctcca gtgggactcc catgctagca ggggtctctg agtatgagct tcccgaagac 2340cctcgctggg agctgcctcg ggacagactg gtcttaggca aacccctggg agagggctgc 2400tttgggcagg tggtgttggc agaggctatc gggctggaca aggacaaacc caaccgtgtg 2460accaaagtgg ctgtgaagat gttgaagtcg gacgcaacag agaaagactt gtcagacctg 2520atctcagaaa tggagatgat gaagatgatc gggaagcata agaatatcat caacctgctg 2580ggggcctgca cgcaggatgg tcccttgtat gtcatcgtgg agtatgcctc caagggcaac 2640ctgcgggagt acctgcaggc ccggaggccc ccagggctgg aatactgcta caaccccagc 2700cacaacccag aggagcagct ctcctccaag gacctggtgt cctgcgccta ccaggtggcc 2760cgaggcatgg agtatctggc ctccaagaag tgcatacacc gagacctggc agccaggaat 2820gtcctggtga cagaggacaa tgtgatgaag atagcagact ttggcctcgc acgggacatt 2880caccacatcg actactataa aaagacaacc aacggccgac tgcctgtgaa gtggatggca 2940cccgaggcat tatttgaccg gatctacacc caccagagtg atgtgtggtc tttcggggtg 3000ctcctgtggg agatcttcac tctgggcggc tccccatacc ccggtgtgcc tgtggaggaa 3060cttttcaagc tgctgaagga gggtcaccgc atggacaagc ccagtaactg caccaacgag 3120ctgtacatga tgatgcggga ctgctggcat gcagtgccct cacagagacc caccttcaag 3180cagctggtgg aagacctgga ccgcatcgtg gccttgacct ccaaccagga gtacctggac 3240ctgtccatgc ccctggacca gtactccccc agctttcccg acacccggag ctctacgtgc 3300tcctcagggg aggattccgt cttctctcat gagccgctgc ccgaggagcc ctgcctgccc 3360cgacacccag cccagcttgc caatggcgga ctcaaacgcc gctgactgcc acccacacgc 3420cctccccaga ctccaccgtc agctgtaacc ctcacccaca gcccctgctg ggcccaccac 3480ctgtccgtcc ctgtcccctt tcctgctggc aggagccggc tgcctaccag gggccttcct 3540gtgtggcctg ccttcacccc actcagctca cctctccctc cacctcctct ccacctgctg 3600gtgagaggtg caaagaggca gatctttgct gccagccact tcatcccctc ccagatgttg 3660gaccaacacc cctccctgcc accaggcact gcctggaggg cagggagtgg gagccaatga 3720acaggcatgc aagtgagagc ttcctgagct ttctcctgtc ggtttggtct gttttgcctt 3780cacccataag cccctcgcac tctggtggca ggtgccttgt cctcagggct acagcagtag 3840ggaggtcagt gcttcgtgcc tcgattgaag gtgacctctg ccccagatag gtggtgccag 3900tggcttatta attccgatac tagtttgctt tgctgaccaa atgcctggta ccagaggatg 3960gtgaggcgaa ggccaggttg ggggcagtgt tgtggccctg gggcccagcc ccaaactggg 4020ggctctgtat atagctatga agaaaacaca aagtgtataa atctgagtat atatttacat 4080gtctttttaa aagggtcgtt accagagatt tacccatcgg gtaagatgct cctggtggct 4140gggaggcatc agttgctata tattaaaaac aaaaaagaaa aaaaaggaaa atgtttttaa 4200aaaggtcata tattttttgc tacttttgct gttttatttt tttaaattat gttctaaacc 4260tattttcagt ttaggtccct caataaaaat tgctgctgct tcatttatct atgggctgta 4320tgaaaagggt gggaatgtcc actggaaaga agggacaccc acgggccctg gggctaggtc 4380tgtcccgagg gcaccgcatg ctcccggcgc aggttccttg taacctcttc ttcctaggtc 4440ctgcacccag acctcacgac gcacctcctg cctctccgct gcttttggaa agtcagaaaa 4500agaagatgtc tgcttcgagg gcaggaaccc catccatgca gtagaggcgc tgggcagaga 4560gtcaaggccc agcagccatc gaccatggat ggtttcctcc aaggaaaccg gtggggttgg 4620gctggggagg gggcacctac ctaggaatag ccacggggta gagctacagt gattaagagg 4680aaagcaaggg cgcggttgct cacgcctgta atcccagcac tttgggacac cgaggtgggc 4740agatcacttc aggtcaggag tttgagacca gcctggccaa cttagtgaaa ccccatctct 4800actaaaaatg caaaaattat ccaggcatgg tggcacacgc ctgtaatccc agctccacag 4860gaggctgagg cagaatccct tgaagctggg aggcggaggt tgcagtgagc cgagattgcg 4920ccattgcact ccagcctggg caacagagaa aacaaaaagg aaaacaaatg atgaaggtct 4980gcagaaactg aaacccagac atgtgtctgc cccctctatg tgggcatggt tttgccagtg 5040cttctaagtg caggagaaca tgtcacctga ggctagtttt gcattcaggt ccctggcttc 5100gtttcttgtt ggtatgcctc cccagatcgt ccttcctgta tccatgtgac cagactgtat 5160ttgttgggac tgtcgcagat cttggcttct tacagttctt cctgtccaaa ctccatcctg 5220tccctcagga acggggggaa aattctccga atgtttttgg ttttttggct gcttggaatt 5280tacttctgcc acctgctggt catcactgtc ctcactaagt ggattctggc tcccccgtac 5340ctcatggctc aaactaccac tcctcagtcg ctatattaaa gcttatattt tgctggatta 5400ctgctaaata caaaagaaag ttcaatatgt tttcatttct gtagggaaaa tgggattgct 5460gctttaaatt tctgagctag ggattttttg gcagctgcag tgttggcgac tattgtaaaa 5520ttctctttgt ttctctctgt aaatagcacc tgctaacatt acaatttgta tttatgttta 5580aagaaggcat catttggtga acagaactag gaaatgaatt tttagctctt aaaagcattt 5640gctttgagac cgcacaggag tgtctttcct tgtaaaacag tgatgataat ttctgccttg 5700gccctacctt gaagcaatgt tgtgtgaagg gatgaagaat ctaaaagtct tcataagtcc 5760ttgggagagg tgctagaaaa atataaggca ctatcataat tacagtgatg tccttgctgt 5820tactactcaa atcacccaca aatttcccca aagactgcgc tagctgtcaa ataaaagaca 5880gtgaaattga cctgaaaaaa aaaaaaaaaa a 591157123DNAHomo sapiensmisc_feature(1)..(7123)nucleotide sequence of human VEGFR1 (CDS 286-4302) 5atcgaggtcc gcgggaggct cggagcgcgc caggcggaca ctcctctcgg ctcctccccg 60gcagcggcgg cggctcggag cgggctccgg ggctcgggtg cagcggccag cgggcgcctg 120gcggcgagga ttacccgggg aagtggttgt ctcctggctg gagccgcgag acgggcgctc 180agggcgcggg gccggcggcg gcgaacgaga ggacggactc tggcggccgg gtcgttggcc 240gcggggagcg cgggcaccgg gcgagcaggc cgcgtcgcgc tcaccatggt cagctactgg 300gacaccgggg tcctgctgtg cgcgctgctc agctgtctgc ttctcacagg atctagttca 360ggttcaaaat taaaagatcc tgaactgagt ttaaaaggca cccagcacat catgcaagca 420ggccagacac tgcatctcca atgcaggggg gaagcagccc ataaatggtc tttgcctgaa 480atggtgagta aggaaagcga aaggctgagc ataactaaat ctgcctgtgg aagaaatggc 540aaacaattct gcagtacttt aaccttgaac acagctcaag caaaccacac tggcttctac 600agctgcaaat atctagctgt

acctacttca aagaagaagg aaacagaatc tgcaatctat 660atatttatta gtgatacagg tagacctttc gtagagatgt acagtgaaat ccccgaaatt 720atacacatga ctgaaggaag ggagctcgtc attccctgcc gggttacgtc acctaacatc 780actgttactt taaaaaagtt tccacttgac actttgatcc ctgatggaaa acgcataatc 840tgggacagta gaaagggctt catcatatca aatgcaacgt acaaagaaat agggcttctg 900acctgtgaag caacagtcaa tgggcatttg tataagacaa actatctcac acatcgacaa 960accaatacaa tcatagatgt ccaaataagc acaccacgcc cagtcaaatt acttagaggc 1020catactcttg tcctcaattg tactgctacc actcccttga acacgagagt tcaaatgacc 1080tggagttacc ctgatgaaaa aaataagaga gcttccgtaa ggcgacgaat tgaccaaagc 1140aattcccatg ccaacatatt ctacagtgtt cttactattg acaaaatgca gaacaaagac 1200aaaggacttt atacttgtcg tgtaaggagt ggaccatcat tcaaatctgt taacacctca 1260gtgcatatat atgataaagc attcatcact gtgaaacatc gaaaacagca ggtgcttgaa 1320accgtagctg gcaagcggtc ttaccggctc tctatgaaag tgaaggcatt tccctcgccg 1380gaagttgtat ggttaaaaga tgggttacct gcgactgaga aatctgctcg ctatttgact 1440cgtggctact cgttaattat caaggacgta actgaagagg atgcagggaa ttatacaatc 1500ttgctgagca taaaacagtc aaatgtgttt aaaaacctca ctgccactct aattgtcaat 1560gtgaaacccc agatttacga aaaggccgtg tcatcgtttc cagacccggc tctctaccca 1620ctgggcagca gacaaatcct gacttgtacc gcatatggta tccctcaacc tacaatcaag 1680tggttctggc acccctgtaa ccataatcat tccgaagcaa ggtgtgactt ttgttccaat 1740aatgaagagt cctttatcct ggatgctgac agcaacatgg gaaacagaat tgagagcatc 1800actcagcgca tggcaataat agaaggaaag aataagatgg ctagcacctt ggttgtggct 1860gactctagaa tttctggaat ctacatttgc atagcttcca ataaagttgg gactgtggga 1920agaaacataa gcttttatat cacagatgtg ccaaatgggt ttcatgttaa cttggaaaaa 1980atgccgacgg aaggagagga cctgaaactg tcttgcacag ttaacaagtt cttatacaga 2040gacgttactt ggattttact gcggacagtt aataacagaa caatgcacta cagtattagc 2100aagcaaaaaa tggccatcac taaggagcac tccatcactc ttaatcttac catcatgaat 2160gtttccctgc aagattcagg cacctatgcc tgcagagcca ggaatgtata cacaggggaa 2220gaaatcctcc agaagaaaga aattacaatc agagatcagg aagcaccata cctcctgcga 2280aacctcagtg atcacacagt ggccatcagc agttccacca ctttagactg tcatgctaat 2340ggtgtccccg agcctcagat cacttggttt aaaaacaacc acaaaataca acaagagcct 2400ggaattattt taggaccagg aagcagcacg ctgtttattg aaagagtcac agaagaggat 2460gaaggtgtct atcactgcaa agccaccaac cagaagggct ctgtggaaag ttcagcatac 2520ctcactgttc aaggaacctc ggacaagtct aatctggagc tgatcactct aacatgcacc 2580tgtgtggctg cgactctctt ctggctccta ttaaccctct ttatccgaaa aatgaaaagg 2640tcttcttctg aaataaagac tgactaccta tcaattataa tggacccaga tgaagttcct 2700ttggatgagc agtgtgagcg gctcccttat gatgccagca agtgggagtt tgcccgggag 2760agacttaaac tgggcaaatc acttggaaga ggggcttttg gaaaagtggt tcaagcatca 2820gcatttggca ttaagaaatc acctacgtgc cggactgtgg ctgtgaaaat gctgaaagag 2880ggggccacgg ccagcgagta caaagctctg atgactgagc taaaaatctt gacccacatt 2940ggccaccatc tgaacgtggt taacctgctg ggagcctgca ccaagcaagg agggcctctg 3000atggtgattg ttgaatactg caaatatgga aatctctcca actacctcaa gagcaaacgt 3060gacttatttt ttctcaacaa ggatgcagca ctacacatgg agcctaagaa agaaaaaatg 3120gagccaggcc tggaacaagg caagaaacca agactagata gcgtcaccag cagcgaaagc 3180tttgcgagct ccggctttca ggaagataaa agtctgagtg atgttgagga agaggaggat 3240tctgacggtt tctacaagga gcccatcact atggaagatc tgatttctta cagttttcaa 3300gtggccagag gcatggagtt cctgtcttcc agaaagtgca ttcatcggga cctggcagcg 3360agaaacattc ttttatctga gaacaacgtg gtgaagattt gtgattttgg ccttgcccgg 3420gatatttata agaaccccga ttatgtgaga aaaggagata ctcgacttcc tctgaaatgg 3480atggctcctg aatctatctt tgacaaaatc tacagcacca agagcgacgt gtggtcttac 3540ggagtattgc tgtgggaaat cttctcctta ggtgggtctc catacccagg agtacaaatg 3600gatgaggact tttgcagtcg cctgagggaa ggcatgagga tgagagctcc tgagtactct 3660actcctgaaa tctatcagat catgctggac tgctggcaca gagacccaaa agaaaggcca 3720agatttgcag aacttgtgga aaaactaggt gatttgcttc aagcaaatgt acaacaggat 3780ggtaaagact acatcccaat caatgccata ctgacaggaa atagtgggtt tacatactca 3840actcctgcct tctctgagga cttcttcaag gaaagtattt cagctccgaa gtttaattca 3900ggaagctctg atgatgtcag atacgtaaat gctttcaagt tcatgagcct ggaaagaatc 3960aaaacctttg aagaactttt accgaatgcc acctccatgt ttgatgacta ccagggcgac 4020agcagcactc tgttggcctc tcccatgctg aagcgcttca cctggactga cagcaaaccc 4080aaggcctcgc tcaagattga cttgagagta accagtaaaa gtaaggagtc ggggctgtct 4140gatgtcagca ggcccagttt ctgccattcc agctgtgggc acgtcagcga aggcaagcgc 4200aggttcacct acgaccacgc tgagctggaa aggaaaatcg cgtgctgctc cccgccccca 4260gactacaact cggtggtcct gtactccacc ccacccatct agagtttgac acgaagcctt 4320atttctagaa gcacatgtgt atttataccc ccaggaaact agcttttgcc agtattatgc 4380atatataagt ttacaccttt atctttccat gggagccagc tgctttttgt gattttttta 4440atagtgcttt tttttttttg actaacaaga atgtaactcc agatagagaa atagtgacaa 4500gtgaagaaca ctactgctaa atcctcatgt tactcagtgt tagagaaatc cttcctaaac 4560ccaatgactt ccctgctcca acccccgcca cctcagggca cgcaggacca gtttgattga 4620ggagctgcac tgatcaccca atgcatcacg taccccactg ggccagccct gcagcccaaa 4680acccagggca acaagcccgt tagccccagg gatcactggc tggcctgagc aacatctcgg 4740gagtcctcta gcaggcctaa gacatgtgag gaggaaaagg aaaaaaagca aaaagcaagg 4800gagaaaagag aaaccgggag aaggcatgag aaagaatttg agacgcacca tgtgggcacg 4860gagggggacg gggctcagca atgccatttc agtggcttcc cagctctgac ccttctacat 4920ttgagggccc agccaggagc agatggacag cgatgagggg acattttctg gattctggga 4980ggcaagaaaa ggacaaatat cttttttgga actaaagcaa attttagaac tttacctatg 5040gaagtggttc tatgtccatt ctcattcgtg gcatgttttg atttgtagca ctgagggtgg 5100cactcaactc tgagcccata cttttggctc ctctagtaag atgcactgaa aacttagcca 5160gagttaggtt gtctccaggc catgatggcc ttacactgaa aatgtcacat tctattttgg 5220gtattaatat atagtccaga cacttaactc aatttcttgg tattattctg ttttgcacag 5280ttagttgtga aagaaagctg agaagaatga aaatgcagtc ctgaggagag gagttttctc 5340catatcaaaa cgagggctga tggaggaaaa aggtcaataa ggtcaaggga aaaccccgtc 5400tctataccaa ccaaaccaat tcaccaacac agttgggacc caaaacacag gaagtcagtc 5460acgtttcctt ttcatttaat ggggattcca ctatctcaca ctaatctgaa aggatgtgga 5520agagcattag ctggcgcata ttaagcactt taagctcctt gagtaaaaag gtggtatgta 5580atttatgcaa ggtatttctc cagttgggac tcaggatatt agttaatgag ccatcactag 5640aagaaaagcc cattttcaac tgctttgaaa cttgcctggg gtctgagcat gatgggaata 5700gggagacagg gtaggaaagg gcgcctactc ttcagggtct aaagatcaag tgggccttgg 5760atcgctaagc tggctctgtt tgatgctatt tatgcaagtt agggtctatg tatttatgat 5820gtctgcacct tctgcagcca gtcagaagct ggagaggcaa cagtggattg ctgcttcttg 5880gggagaagag tatgcttcct tttatccatg taatttaact gtagaacctg agctctaagt 5940aaccgaagaa tgtatgcctc tgttcttatg tgccacatcc ttgtttaaag gctctctgta 6000tgaagagatg ggaccgtcat cagcacattc cctagtgagc ctactggctc ctggcagcgg 6060cttttgtgga agactcacta gccagaagag aggagtggga cagtcctctc caccaagatc 6120taaatccaaa caaaagcagg ctagagccag aagagaggac aaatctttgt tcttcctctt 6180ctttacatac gcaaaccacc tgtgacagct ggcaatttta taaatcaggt aactggaagg 6240aggttaaaca cagaaaaaag aagacctcag tcaattctct actttttttt ttttttccaa 6300atcagataat agcccagcaa atagtgataa caaataaaac cttagctatt catgtcttga 6360tttcaataat taattcttaa tcattaagag accataataa atactccttt tcaagagaaa 6420agcaaaacca ttagaattgt tactcagctc cttcaaactc aggtttgtag catacatgag 6480tccatccatc agtcaaagaa tggttccatc tggagtctta atgtagaaag aaaaatggag 6540acttgtaata atgagctagt tacaaagtgc ttgttcatta aaatagcact gaaaattgaa 6600acatgaatta actgataata ttccaatcat ttgccattta tgacaaaaat ggttggcact 6660aacaaagaac gagcacttcc tttcagagtt tctgagataa tgtacgtgga acagtctggg 6720tggaatgggg ctgaaaccat gtgcaagtct gtgtcttgtc agtccaagaa gtgacaccga 6780gatgttaatt ttagggaccc gtgccttgtt tcctagccca caagaatgca aacatcaaac 6840agatactcgc tagcctcatt taaattgatt aaaggaggag tgcatctttg gccgacagtg 6900gtgtaactgt atgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgggt gtatgtgtgt 6960tttgtgcata actatttaag gaaactggaa ttttaaagtt acttttatac aaaccaagaa 7020tatatgctac agatataaga cagacatggt ttggtcctat atttctagtc atgatgaatg 7080tattttgtat accatcttca tataataaac ttccaaaaac aca 712366055DNAHomo sapiensmisc_feature(1)..(6055)nucleotide sequence of human VEGFR2 (CDS 303-4373) 6actgagtccc gggaccccgg gagagcggtc aatgtgtggt cgctgcgttt cctctgcctg 60cgccgggcat cacttgcgcg ccgcagaaag tccgtctggc agcctggata tcctctccta 120ccggcacccg cagacgcccc tgcagccgcg gtcggcgccc gggctcccta gccctgtgcg 180ctcaactgtc ctgcgctgcg gggtgccgcg agttccacct ccgcgcctcc ttctctagac 240aggcgctggg agaaagaacc ggctcccgag ttctgggcat ttcgcccggc tcgaggtgca 300ggatgcagag caaggtgctg ctggccgtcg ccctgtggct ctgcgtggag acccgggccg 360cctctgtggg tttgcctagt gtttctcttg atctgcccag gctcagcata caaaaagaca 420tacttacaat taaggctaat acaactcttc aaattacttg caggggacag agggacttgg 480actggctttg gcccaataat cagagtggca gtgagcaaag ggtggaggtg actgagtgca 540gcgatggcct cttctgtaag acactcacaa ttccaaaagt gatcggaaat gacactggag 600cctacaagtg cttctaccgg gaaactgact tggcctcggt catttatgtc tatgttcaag 660attacagatc tccatttatt gcttctgtta gtgaccaaca tggagtcgtg tacattactg 720agaacaaaaa caaaactgtg gtgattccat gtctcgggtc catttcaaat ctcaacgtgt 780cactttgtgc aagataccca gaaaagagat ttgttcctga tggtaacaga atttcctggg 840acagcaagaa gggctttact attcccagct acatgatcag ctatgctggc atggtcttct 900gtgaagcaaa aattaatgat gaaagttacc agtctattat gtacatagtt gtcgttgtag 960ggtataggat ttatgatgtg gttctgagtc cgtctcatgg aattgaacta tctgttggag 1020aaaagcttgt cttaaattgt acagcaagaa ctgaactaaa tgtggggatt gacttcaact 1080gggaataccc ttcttcgaag catcagcata agaaacttgt aaaccgagac ctaaaaaccc 1140agtctgggag tgagatgaag aaatttttga gcaccttaac tatagatggt gtaacccgga 1200gtgaccaagg attgtacacc tgtgcagcat ccagtgggct gatgaccaag aagaacagca 1260catttgtcag ggtccatgaa aaaccttttg ttgcttttgg aagtggcatg gaatctctgg 1320tggaagccac ggtgggggag cgtgtcagaa tccctgcgaa gtaccttggt tacccacccc 1380cagaaataaa atggtataaa aatggaatac cccttgagtc caatcacaca attaaagcgg 1440ggcatgtact gacgattatg gaagtgagtg aaagagacac aggaaattac actgtcatcc 1500ttaccaatcc catttcaaag gagaagcaga gccatgtggt ctctctggtt gtgtatgtcc 1560caccccagat tggtgagaaa tctctaatct ctcctgtgga ttcctaccag tacggcacca 1620ctcaaacgct gacatgtacg gtctatgcca ttcctccccc gcatcacatc cactggtatt 1680ggcagttgga ggaagagtgc gccaacgagc ccagccaagc tgtctcagtg acaaacccat 1740acccttgtga agaatggaga agtgtggagg acttccaggg aggaaataaa attgaagtta 1800ataaaaatca atttgctcta attgaaggaa aaaacaaaac tgtaagtacc cttgttatcc 1860aagcggcaaa tgtgtcagct ttgtacaaat gtgaagcggt caacaaagtc gggagaggag 1920agagggtgat ctccttccac gtgaccaggg gtcctgaaat tactttgcaa cctgacatgc 1980agcccactga gcaggagagc gtgtctttgt ggtgcactgc agacagatct acgtttgaga 2040acctcacatg gtacaagctt ggcccacagc ctctgccaat ccatgtggga gagttgccca 2100cacctgtttg caagaacttg gatactcttt ggaaattgaa tgccaccatg ttctctaata 2160gcacaaatga cattttgatc atggagctta agaatgcatc cttgcaggac caaggagact 2220atgtctgcct tgctcaagac aggaagacca agaaaagaca ttgcgtggtc aggcagctca 2280cagtcctaga gcgtgtggca cccacgatca caggaaacct ggagaatcag acgacaagta 2340ttggggaaag catcgaagtc tcatgcacgg catctgggaa tccccctcca cagatcatgt 2400ggtttaaaga taatgagacc cttgtagaag actcaggcat tgtattgaag gatgggaacc 2460ggaacctcac tatccgcaga gtgaggaagg aggacgaagg cctctacacc tgccaggcat 2520gcagtgttct tggctgtgca aaagtggagg catttttcat aatagaaggt gcccaggaaa 2580agacgaactt ggaaatcatt attctagtag gcacggcggt gattgccatg ttcttctggc 2640tacttcttgt catcatccta cggaccgtta agcgggccaa tggaggggaa ctgaagacag 2700gctacttgtc catcgtcatg gatccagatg aactcccatt ggatgaacat tgtgaacgac 2760tgccttatga tgccagcaaa tgggaattcc ccagagaccg gctgaagcta ggtaagcctc 2820ttggccgtgg tgcctttggc caagtgattg aagcagatgc ctttggaatt gacaagacag 2880caacttgcag gacagtagca gtcaaaatgt tgaaagaagg agcaacacac agtgagcatc 2940gagctctcat gtctgaactc aagatcctca ttcatattgg tcaccatctc aatgtggtca 3000accttctagg tgcctgtacc aagccaggag ggccactcat ggtgattgtg gaattctgca 3060aatttggaaa cctgtccact tacctgagga gcaagagaaa tgaatttgtc ccctacaaga 3120ccaaaggggc acgattccgt caagggaaag actacgttgg agcaatccct gtggatctga 3180aacggcgctt ggacagcatc accagtagcc agagctcagc cagctctgga tttgtggagg 3240agaagtccct cagtgatgta gaagaagagg aagctcctga agatctgtat aaggacttcc 3300tgaccttgga gcatctcatc tgttacagct tccaagtggc taagggcatg gagttcttgg 3360catcgcgaaa gtgtatccac agggacctgg cggcacgaaa tatcctctta tcggagaaga 3420acgtggttaa aatctgtgac tttggcttgg cccgggatat ttataaagat ccagattatg 3480tcagaaaagg agatgctcgc ctccctttga aatggatggc cccagaaaca atttttgaca 3540gagtgtacac aatccagagt gacgtctggt cttttggtgt tttgctgtgg gaaatatttt 3600ccttaggtgc ttctccatat cctggggtaa agattgatga agaattttgt aggcgattga 3660aagaaggaac tagaatgagg gcccctgatt atactacacc agaaatgtac cagaccatgc 3720tggactgctg gcacggggag cccagtcaga gacccacgtt ttcagagttg gtggaacatt 3780tgggaaatct cttgcaagct aatgctcagc aggatggcaa agactacatt gttcttccga 3840tatcagagac tttgagcatg gaagaggatt ctggactctc tctgcctacc tcacctgttt 3900cctgtatgga ggaggaggaa gtatgtgacc ccaaattcca ttatgacaac acagcaggaa 3960tcagtcagta tctgcagaac agtaagcgaa agagccggcc tgtgagtgta aaaacatttg 4020aagatatccc gttagaagaa ccagaagtaa aagtaatccc agatgacaac cagacggaca 4080gtggtatggt tcttgcctca gaagagctga aaactttgga agacagaacc aaattatctc 4140catcttttgg tggaatggtg cccagcaaaa gcagggagtc tgtggcatct gaaggctcaa 4200accagacaag cggctaccag tccggatatc actccgatga cacagacacc accgtgtact 4260ccagtgagga agcagaactt ttaaagctga tagagattgg agtgcaaacc ggtagcacag 4320cccagattct ccagcctgac tcggggacca cactgagctc tcctcctgtt taaaaggaag 4380catccacacc cccaactcct ggacatcaca tgagaggtgc tgctcagatt ttcaagtgtt 4440gttctttcca ccagcaggaa gtagccgcat ttgattttca tttcgacaac agaaaaagga 4500cctcggactg cagggagcca gtcttctagg catatcctgg aagaggcttg tgacccaaga 4560atgtgtctgt gtcttctccc agtgttgacc tgatcctctt tttcattcat ttaaaaagca 4620tttatcatgc cccctgctgc gggtctcacc atgggtttag aacaaagacg ttcaagaaat 4680ggccccatcc tcaaagaagt agcagtacct ggggagctga cacttctgta aaactagaag 4740ataaaccagg caatgtaagt gttcgaggtg ttgaagatgg gaaggatttg cagggctgag 4800tctatccaag aggctttgtt taggacgtgg gtcccaagcc aagccttaag tgtggaattc 4860ggattgatag aaaggaagac taacgttacc ttgctttgga gagtactgga gcctgcaaat 4920gcattgtgtt tgctctggtg gaggtgggca tggggtctgt tctgaaatgt aaagggttca 4980gacggggttt ctggttttag aaggttgcgt gttcttcgag ttgggctaaa gtagagttcg 5040ttgtgctgtt tctgactcct aatgagagtt ccttccagac cgttacgtgt ctcctggcca 5100agccccagga aggaaatgat gcagctctgg ctccttgtct cccaggctga tcctttattc 5160agaataccac aaagaaagga cattcagctc aaggctccct gccgtgttga agagttctga 5220ctgcacaaac cagcttctgg tttcttctgg aatgaatacc ctcatatctg tcctgatgtg 5280atatgtctga gactgaatgc gggaggttca atgtgaagct gtgtgtggtg tcaaagtttc 5340aggaaggatt ttaccctttt gttcttcccc ctgtccccaa cccactctca ccccgcaacc 5400catcagtatt ttagttattt ggcctctact ccagtaaacc tgattgggtt tgttcactct 5460ctgaatgatt attagccaga cttcaaaatt attttatagc ccaaattata acatctattg 5520tattatttag acttttaaca tatagagcta tttctactga tttttgccct tgttctgtcc 5580tttttttcaa aaaagaaaat gtgttttttg tttggtacca tagtgtgaaa tgctgggaac 5640aatgactata agacatgcta tggcacatat atttatagtc tgtttatgta gaaacaaatg 5700taatatatta aagccttata tataatgaac tttgtactat tcacattttg tatcagtatt 5760atgtagcata acaaaggtca taatgctttc agcaattgat gtcattttat taaagaacat 5820tgaaaaactt gaaggaatcc ctttgcaagg ttgcattact gtacccatca tttctaaaat 5880ggaagagggg gtggctgggc acagtggccg acacctaaaa acccagcact ttggggggcc 5940aaggtgggag gatcgcttga gcccaggagt tcaagaccag tctggccaac atggtcagat 6000tccatctcaa agaaaaaagg taaaaataaa ataaaatgga gaagaaggaa tcaga 60557223PRTHomo sapiensMISC_FEATURE(1)..(223)amino acid sequence of human IgG Fc 7Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 1 5 10 15 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 20 25 30 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 35 40 45 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 50 55 60 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 65 70 75 80 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 85 90 95 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 100 105 110 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 115 120 125 Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 130 135 140 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 145 150 155 160 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 165 170 175 Asp Gly Pro Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 180 185 190 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 195 200 205 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 220 8669DNAHomo sapiensmisc_feature(1)..(669)DNA sequence of human IgG FC 8acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc 60ccaaaaccca aggacaccct catgatctcc cggacccctg aggtcacatg cgtggtggtg 120gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg 180cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc 240gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc 300aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga 360gaaccacagg tgtacaccct gcccccatcc cgggatgagc tgaccaagaa ccaggtcagc 420ctgacctgcc tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat 480gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggccccttc 540ttcctctaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca 600tgctccgtga tgcatgaggc tctgcacaac cactacacgc agaagagcct ctccctgtct 660ccgggtaaa 6699580PRTArtificial sequence#19 fusion protein 9Arg Pro Ser Pro Thr Leu

Pro Glu Gln Ala Gln Pro Trp Gly Ala Pro 1 5 10 15 Val Glu Val Glu Ser Phe Leu Val His Pro Gly Asp Leu Leu Gln Leu 20 25 30 Arg Cys Arg Leu Arg Asp Asp Val Gln Ser Ile Asn Trp Leu Arg Asp 35 40 45 Gly Val Gln Leu Ala Glu Ser Asn Arg Thr Arg Ile Thr Gly Glu Glu 50 55 60 Val Glu Val Gln Asp Ser Val Pro Ala Asp Ser Gly Leu Tyr Ala Cys 65 70 75 80 Val Thr Ser Ser Pro Ser Gly Ser Asp Thr Thr Tyr Phe Ser Val Asn 85 90 95 Val Ser Asp Ala Leu Pro Ser Ser Glu Asp Asp Asp Asp Asp Asp Asp 100 105 110 Ser Ser Ser Glu Glu Lys Glu Thr Asp Asn Thr Lys Pro Asn Pro Val 115 120 125 Ala Pro Tyr Trp Thr Ser Pro Glu Lys Met Glu Lys Lys Leu His Ala 130 135 140 Val Pro Ala Ala Lys Thr Val Lys Phe Lys Cys Pro Ser Ser Gly Thr 145 150 155 160 Pro Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro 165 170 175 Asp His Arg Ile Gly Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile 180 185 190 Ile Met Asp Ser Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys Ile 195 200 205 Val Glu Asn Glu Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp Val 210 215 220 Val Glu Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala 225 230 235 240 Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met Cys Lys Val 245 250 255 Tyr Ser Asp Pro Gln Pro His Ile Gln Trp Leu Lys His Ile Glu Val 260 265 270 Asn Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro Tyr Val Gln Ile Leu 275 280 285 Lys Thr Ala Gly Val Asn Thr Thr Asp Lys Glu Met Glu Val Leu His 290 295 300 Leu Arg Asn Val Ser Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala 305 310 315 320 Gly Asn Ser Ile Gly Leu Ser His His Ser Ala Trp Leu Thr Val Leu 325 330 335 Glu Ala Leu Glu Glu Arg Pro Ala Val Met Thr Ser Pro Leu Tyr Leu 340 345 350 Glu Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 355 360 365 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 370 375 380 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 385 390 395 400 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 405 410 415 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 420 425 430 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 435 440 445 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 450 455 460 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 465 470 475 480 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 485 490 495 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 500 505 510 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 515 520 525 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 530 535 540 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 545 550 555 560 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 565 570 575 Ser Pro Gly Lys 580 10526PRTArtificial sequence#13 fusion protein 10Lys Asn Arg Thr Arg Ile Thr Gly Glu Glu Val Glu Val Gln Asp Ser 1 5 10 15 Val Pro Ala Asp Ser Gly Leu Tyr Ala Cys Val Thr Ser Ser Pro Ser 20 25 30 Gly Ser Asp Thr Thr Tyr Phe Ser Val Asn Val Ser Asp Ala Leu Pro 35 40 45 Ser Ser Glu Asp Asp Asp Asp Asp Asp Asp Ser Ser Ser Glu Glu Lys 50 55 60 Glu Thr Asp Asn Thr Lys Pro Asn Pro Val Ala Pro Tyr Trp Thr Ser 65 70 75 80 Pro Glu Lys Met Glu Lys Lys Leu His Ala Val Pro Ala Ala Lys Thr 85 90 95 Val Lys Phe Lys Cys Pro Ser Ser Gly Thr Pro Asn Pro Thr Leu Arg 100 105 110 Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly 115 120 125 Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile Ile Met Asp Ser Val Val 130 135 140 Pro Ser Asp Lys Gly Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr Gly 145 150 155 160 Ser Ile Asn His Thr Tyr Gln Leu Asp Val Val Glu Arg Ser Pro His 165 170 175 Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala Asn Lys Thr Val Ala Leu 180 185 190 Gly Ser Asn Val Glu Phe Met Cys Lys Val Tyr Ser Asp Pro Gln Pro 195 200 205 His Ile Gln Trp Leu Lys His Ile Glu Val Asn Gly Ser Lys Ile Gly 210 215 220 Pro Asp Asn Leu Pro Tyr Val Gln Ile Leu Lys Thr Ala Gly Val Asn 225 230 235 240 Thr Thr Asp Lys Glu Met Glu Val Leu His Leu Arg Asn Val Ser Phe 245 250 255 Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Leu 260 265 270 Ser His His Ser Ala Trp Leu Thr Val Leu Glu Ala Leu Glu Glu Arg 275 280 285 Pro Ala Val Met Thr Ser Pro Leu Tyr Leu Glu Asp Lys Thr His Thr 290 295 300 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 305 310 315 320 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 325 330 335 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 340 345 350 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 355 360 365 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 370 375 380 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 385 390 395 400 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 405 410 415 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 420 425 430 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 435 440 445 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 450 455 460 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 465 470 475 480 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 485 490 495 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 500 505 510 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 515 520 525 11500PRTArtificial sequence#22 fusion protein 11Val Thr Ser Ser Pro Ser Gly Ser Asp Thr Thr Tyr Phe Ser Val Asn 1 5 10 15 Val Ser Asp Ala Leu Pro Ser Ser Glu Asp Asp Asp Asp Asp Asp Asp 20 25 30 Ser Ser Ser Glu Glu Lys Glu Thr Asp Asn Thr Lys Pro Asn Pro Val 35 40 45 Ala Pro Tyr Trp Thr Ser Pro Glu Lys Met Glu Lys Lys Leu His Ala 50 55 60 Val Pro Ala Ala Lys Thr Val Lys Phe Lys Cys Pro Ser Ser Gly Thr 65 70 75 80 Pro Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro 85 90 95 Asp His Arg Ile Gly Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile 100 105 110 Ile Met Asp Ser Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys Ile 115 120 125 Val Glu Asn Glu Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp Val 130 135 140 Val Glu Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala 145 150 155 160 Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met Cys Lys Val 165 170 175 Tyr Ser Asp Pro Gln Pro His Ile Gln Trp Leu Lys His Ile Glu Val 180 185 190 Asn Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro Tyr Val Gln Ile Leu 195 200 205 Lys Thr Ala Gly Val Asn Thr Thr Asp Lys Glu Met Glu Val Leu His 210 215 220 Leu Arg Asn Val Ser Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala 225 230 235 240 Gly Asn Ser Ile Gly Leu Ser His His Ser Ala Trp Leu Thr Val Leu 245 250 255 Glu Ala Leu Glu Glu Arg Pro Ala Val Met Thr Ser Pro Leu Tyr Leu 260 265 270 Glu Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 275 280 285 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 290 295 300 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 305 310 315 320 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 325 330 335 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 340 345 350 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 385 390 395 400 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 405 410 415 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 420 425 430 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 435 440 445 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 450 455 460 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 465 470 475 480 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495 Ser Pro Gly Lys 500 12468PRTArtificial sequence#23 fusion protein 12Ser Ser Ser Glu Glu Lys Glu Thr Asp Asn Thr Lys Pro Asn Pro Val 1 5 10 15 Ala Pro Tyr Trp Thr Ser Pro Glu Lys Met Glu Lys Lys Leu His Ala 20 25 30 Val Pro Ala Ala Lys Thr Val Lys Phe Lys Cys Pro Ser Ser Gly Thr 35 40 45 Pro Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro 50 55 60 Asp His Arg Ile Gly Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile 65 70 75 80 Ile Met Asp Ser Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys Ile 85 90 95 Val Glu Asn Glu Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp Val 100 105 110 Val Glu Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala 115 120 125 Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met Cys Lys Val 130 135 140 Tyr Ser Asp Pro Gln Pro His Ile Gln Trp Leu Lys His Ile Glu Val 145 150 155 160 Asn Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro Tyr Val Gln Ile Leu 165 170 175 Lys Thr Ala Gly Val Asn Thr Thr Asp Lys Glu Met Glu Val Leu His 180 185 190 Leu Arg Asn Val Ser Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala 195 200 205 Gly Asn Ser Ile Gly Leu Ser His His Ser Ala Trp Leu Thr Val Leu 210 215 220 Glu Ala Leu Glu Glu Arg Pro Ala Val Met Thr Ser Pro Leu Tyr Leu 225 230 235 240 Glu Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 245 250 255 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 260 265 270 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 275 280 285 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 290 295 300 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 305 310 315 320 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 325 330 335 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 340 345 350 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 355 360 365 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 370 375 380 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 385 390 395 400 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 405 410 415 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 420 425 430 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 435 440 445 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 450 455 460 Ser Pro Gly Lys 465 13457PRTArtificial sequence#26 fusion protein 13Lys Pro Asn Pro Val Ala Pro Tyr Trp Thr Ser Pro Glu Lys Met Glu 1 5 10 15 Lys Lys Leu His Ala Val Pro Ala Ala Lys Thr Val Lys Phe Lys Cys 20 25 30 Pro Ser Ser Gly Thr Pro Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly 35 40 45 Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly Tyr Lys Val Arg Tyr 50 55 60 Ala Thr Trp Ser Ile Ile Met Asp Ser Val Val Pro Ser Asp Lys Gly 65 70 75 80 Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr Gly Ser Ile Asn His Thr 85 90 95 Tyr Gln Leu Asp Val Val Glu Arg Ser Pro His Arg Pro Ile Leu Gln 100 105 110 Ala Gly Leu Pro Ala Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu 115 120 125 Phe Met Cys Lys Val Tyr Ser Asp Pro Gln Pro His Ile Gln Trp Leu 130 135 140 Lys His Ile Glu Val Asn Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro 145 150 155 160 Tyr Val Gln Ile Leu Lys Thr Ala Gly Val Asn Thr Thr Asp Lys Glu 165 170 175 Met Glu Val Leu His Leu Arg Asn Val Ser Phe Glu Asp Ala Gly Glu 180 185 190 Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Leu Ser His His Ser Ala 195 200 205 Trp Leu Thr Val Leu Glu Ala

Leu Glu Glu Arg Pro Ala Val Met Thr 210 215 220 Ser Pro Leu Tyr Leu Glu Asp Lys Thr His Thr Cys Pro Pro Cys Pro 225 230 235 240 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 245 250 255 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 260 265 270 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 275 280 285 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 290 295 300 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 305 310 315 320 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 325 330 335 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 340 345 350 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 355 360 365 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 370 375 380 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 385 390 395 400 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 405 410 415 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 420 425 430 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 435 440 445 Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 14451PRTArtificial sequence#29 fusion protein 14Pro Tyr Trp Thr Ser Pro Glu Lys Met Glu Lys Lys Leu His Ala Val 1 5 10 15 Pro Ala Ala Lys Thr Val Lys Phe Lys Cys Pro Ser Ser Gly Thr Pro 20 25 30 Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro Asp 35 40 45 His Arg Ile Gly Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile Ile 50 55 60 Met Asp Ser Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys Ile Val 65 70 75 80 Glu Asn Glu Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp Val Val 85 90 95 Glu Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala Asn 100 105 110 Lys Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met Cys Lys Val Tyr 115 120 125 Ser Asp Pro Gln Pro His Ile Gln Trp Leu Lys His Ile Glu Val Asn 130 135 140 Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro Tyr Val Gln Ile Leu Lys 145 150 155 160 Thr Ala Gly Val Asn Thr Thr Asp Lys Glu Met Glu Val Leu His Leu 165 170 175 Arg Asn Val Ser Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala Gly 180 185 190 Asn Ser Ile Gly Leu Ser His His Ser Ala Trp Leu Thr Val Leu Glu 195 200 205 Ala Leu Glu Glu Arg Pro Ala Val Met Thr Ser Pro Leu Tyr Leu Glu 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 15446PRTArtificial sequence#8 fusion protein 15Pro Glu Lys Met Glu Lys Lys Leu His Ala Val Pro Ala Ala Lys Thr 1 5 10 15 Val Lys Phe Lys Cys Pro Ser Ser Gly Thr Pro Asn Pro Thr Leu Arg 20 25 30 Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly 35 40 45 Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile Ile Met Asp Ser Val Val 50 55 60 Pro Ser Asp Lys Gly Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr Gly 65 70 75 80 Ser Ile Asn His Thr Tyr Gln Leu Asp Val Val Glu Arg Ser Pro His 85 90 95 Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala Asn Lys Thr Val Ala Leu 100 105 110 Gly Ser Asn Val Glu Phe Met Cys Lys Val Tyr Ser Asp Pro Gln Pro 115 120 125 His Ile Gln Trp Leu Lys His Ile Glu Val Asn Gly Ser Lys Ile Gly 130 135 140 Pro Asp Asn Leu Pro Tyr Val Gln Ile Leu Lys Thr Ala Gly Val Asn 145 150 155 160 Thr Thr Asp Lys Glu Met Glu Val Leu His Leu Arg Asn Val Ser Phe 165 170 175 Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Leu 180 185 190 Ser His His Ser Ala Trp Leu Thr Val Leu Glu Ala Leu Glu Glu Arg 195 200 205 Pro Ala Val Met Thr Ser Pro Leu Tyr Leu Glu Asp Lys Thr His Thr 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 260 265 270 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 16 1743DNAArtificial sequencenucleotide sequence of #19 fusion protein 16aggccgtccc cgaccttgcc tgaacaagcc cagccctggg gagcccctgt ggaagtggag 60tccttcctgg tccaccccgg tgacctgcta cagcttcgct gtcggctgcg ggacgatgtg 120cagagcatca actggctgcg ggacggggtg cagctggcgg aaagcaatcg cacccgcatc 180acaggggagg aggtggaggt gcaggactcc gtgcccgcag actccggcct ctatgcttgc 240gtaaccagca gcccctcggg cagtgacacc acctacttct ccgtcaatgt ttcagatgct 300ctcccctcct cggaggatga tgatgatgat gatgactcct cttcagagga gaaagaaaca 360gataacacca aaccaaaccc cgtagctcca tattggacat ccccagaaaa gatggaaaag 420aaattgcatg cagtgccggc tgccaagaca gtgaagttca aatgcccttc cagtgggacc 480ccaaacccca cactgcgctg gttgaaaaat ggcaaagaat tcaaacctga ccacagaatt 540ggaggctaca aggtccgtta tgccacctgg agcatcataa tggactctgt ggtgccctct 600gacaagggca actacacctg cattgtggag aatgagtacg gcagcatcaa ccacacatac 660cagctggatg tcgtggagcg gtcccctcac cggcccatcc tgcaagcagg gttgcccgcc 720aacaaaacag tggccctggg tagcaacgtg gagttcatgt gtaaggtgta cagtgacccg 780cagccgcaca tccagtggct aaagcacatc gaggtgaatg ggagcaagat tggcccagac 840aacctgcctt atgtccagat cttgaagact gctggagtta ataccaccga caaagagatg 900gaggtgcttc acttaagaaa tgtctccttt gaggacgcag gggagtatac gtgcttggcg 960ggtaactcta tcggactctc ccatcactct gcatggttga ccgttctgga agccctggaa 1020gagaggccgg cagtgatgac ctcgcccctg tacctggagg acaaaactca cacatgccca 1080ccgtgcccag cacctgaact cctgggggga ccgtcagtct tcctcttccc cccaaaaccc 1140aaggacaccc tcatgatctc ccggacccct gaggtcacat gcgtggtggt ggacgtgagc 1200cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc 1260aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc 1320gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc 1380ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag 1440gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc 1500ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg 1560gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctac 1620agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg 1680atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa 1740tga 1743171581DNAArtificial sequencenucleotide sequence of #13 fusion protein 17aaaaatcgca cccgcatcac aggggaggag gtggaggtgc aggactccgt gcccgcagac 60tccggcctct atgcttgcgt aaccagcagc ccctcgggca gtgacaccac ctacttctcc 120gtcaatgttt cagatgctct cccctcctcg gaggatgatg atgatgatga tgactcctct 180tcagaggaga aagaaacaga taacaccaaa ccaaaccccg tagctccata ttggacatcc 240ccagaaaaga tggaaaagaa attgcatgca gtgccggctg ccaagacagt gaagttcaaa 300tgcccttcca gtgggacccc aaaccccaca ctgcgctggt tgaaaaatgg caaagaattc 360aaacctgacc acagaattgg aggctacaag gtccgttatg ccacctggag catcataatg 420gactctgtgg tgccctctga caagggcaac tacacctgca ttgtggagaa tgagtacggc 480agcatcaacc acacatacca gctggatgtc gtggagcggt cccctcaccg gcccatcctg 540caagcagggt tgcccgccaa caaaacagtg gccctgggta gcaacgtgga gttcatgtgt 600aaggtgtaca gtgacccgca gccgcacatc cagtggctaa agcacatcga ggtgaatggg 660agcaagattg gcccagacaa cctgccttat gtccagatct tgaagactgc tggagttaat 720accaccgaca aagagatgga ggtgcttcac ttaagaaatg tctcctttga ggacgcaggg 780gagtatacgt gcttggcggg taactctatc ggactctccc atcactctgc atggttgacc 840gttctggaag ccctggaaga gaggccggca gtgatgacct cgcccctgta cctggaggac 900aaaactcaca catgcccacc gtgcccagca cctgaactcc tggggggacc gtcagtcttc 960ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacatgc 1020gtggtggtgg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc 1080gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt 1140gtggtcagcg tcctcaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc 1200aaggtctcca acaaagccct cccagccccc atcgagaaaa ccatctccaa agccaaaggg 1260cagccccgag aaccacaggt gtacaccctg cccccatccc gggatgagct gaccaagaac 1320caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg 1380gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac 1440ggctccttct tcctctacag caagctcacc gtggacaaga gcaggtggca gcaggggaac 1500gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc 1560tccctgtctc cgggtaaatg a 1581181503DNAArtificial sequencenucleotide sequence of #22 fusion protein 18gtaaccagca gcccctcggg cagtgacacc acctacttct ccgtcaatgt ttcagatgct 60ctcccctcct cggaggatga tgatgatgat gatgactcct cttcagagga gaaagaaaca 120gataacacca aaccaaaccc cgtagctcca tattggacat ccccagaaaa gatggaaaag 180aaattgcatg cagtgccggc tgccaagaca gtgaagttca aatgcccttc cagtgggacc 240ccaaacccca cactgcgctg gttgaaaaat ggcaaagaat tcaaacctga ccacagaatt 300ggaggctaca aggtccgtta tgccacctgg agcatcataa tggactctgt ggtgccctct 360gacaagggca actacacctg cattgtggag aatgagtacg gcagcatcaa ccacacatac 420cagctggatg tcgtggagcg gtcccctcac cggcccatcc tgcaagcagg gttgcccgcc 480aacaaaacag tggccctggg tagcaacgtg gagttcatgt gtaaggtgta cagtgacccg 540cagccgcaca tccagtggct aaagcacatc gaggtgaatg ggagcaagat tggcccagac 600aacctgcctt atgtccagat cttgaagact gctggagtta ataccaccga caaagagatg 660gaggtgcttc acttaagaaa tgtctccttt gaggacgcag gggagtatac gtgcttggcg 720ggtaactcta tcggactctc ccatcactct gcatggttga ccgttctgga agccctggaa 780gagaggccgg cagtgatgac ctcgcccctg tacctggagg acaaaactca cacatgccca 840ccgtgcccag cacctgaact cctgggggga ccgtcagtct tcctcttccc cccaaaaccc 900aaggacaccc tcatgatctc ccggacccct gaggtcacat gcgtggtggt ggacgtgagc 960cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc 1020aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc 1080gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc 1140ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag 1200gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc 1260ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg 1320gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctac 1380agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg 1440atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa 1500tga 1503191407DNAArtificial sequencenucleotide sequence of #23 fusion protein 19tcctcttcag aggagaaaga aacagataac accaaaccaa accccgtagc tccatattgg 60acatccccag aaaagatgga aaagaaattg catgcagtgc cggctgccaa gacagtgaag 120ttcaaatgcc cttccagtgg gaccccaaac cccacactgc gctggttgaa aaatggcaaa 180gaattcaaac ctgaccacag aattggaggc tacaaggtcc gttatgccac ctggagcatc 240ataatggact ctgtggtgcc ctctgacaag ggcaactaca cctgcattgt ggagaatgag 300tacggcagca tcaaccacac ataccagctg gatgtcgtgg agcggtcccc tcaccggccc 360atcctgcaag cagggttgcc cgccaacaaa acagtggccc tgggtagcaa cgtggagttc 420atgtgtaagg tgtacagtga cccgcagccg cacatccagt ggctaaagca catcgaggtg 480aatgggagca agattggccc agacaacctg ccttatgtcc agatcttgaa gactgctgga 540gttaatacca ccgacaaaga gatggaggtg cttcacttaa gaaatgtctc ctttgaggac 600gcaggggagt atacgtgctt ggcgggtaac tctatcggac tctcccatca ctctgcatgg 660ttgaccgttc tggaagccct ggaagagagg ccggcagtga tgacctcgcc cctgtacctg 720gaggacaaaa ctcacacatg cccaccgtgc ccagcacctg aactcctggg gggaccgtca 780gtcttcctct tccccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc 840acatgcgtgg tggtggacgt gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg 900gacggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg 960taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtac 1020aagtgcaagg tctccaacaa agccctccca gcccccatcg agaaaaccat ctccaaagcc 1080aaagggcagc cccgagaacc acaggtgtac accctgcccc catcccggga tgagctgacc 1140aagaaccagg tcagcctgac ctgcctggtc aaaggcttct atcccagcga catcgccgtg 1200gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac 1260tccgacggct ccttcttcct ctacagcaag ctcaccgtgg acaagagcag gtggcagcag 1320gggaacgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacgcagaag 1380agcctctccc tgtctccggg taaatga 1407201374DNAArtificial sequencenucleotide sequence of #26 fusion protein 20aaacctaacc ccgtagctcc atattggaca tccccagaaa agatggaaaa gaaattgcat 60gcagtgccgg ctgccaagac agtgaagttc aaatgccctt ccagtgggac cccaaacccc 120acactgcgct ggttgaaaaa tggcaaagaa ttcaaacctg accacagaat tggaggctac 180aaggtccgtt atgccacctg gagcatcata atggactctg tggtgccctc tgacaagggc 240aactacacct gcattgtgga gaatgagtac ggcagcatca accacacata ccagctggat 300gtcgtggagc ggtcccctca ccggcccatc ctgcaagcag ggttgcccgc caacaaaaca 360gtggccctgg gtagcaacgt ggagttcatg tgtaaggtgt acagtgaccc gcagccgcac 420atccagtggc taaagcacat cgaggtgaat gggagcaaga ttggcccaga caacctgcct 480tatgtccaga tcttgaagac tgctggagtt aataccaccg acaaagagat ggaggtgctt 540cacttaagaa atgtctcctt tgaggacgca ggggagtata cgtgcttggc gggtaactct 600atcggactct cccatcactc tgcatggttg accgttctgg aagccctgga agagaggccg 660gcagtgatga cctcgcccct gtacctggag gacaaaactc acacatgccc accgtgccca 720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc 780ctcatgatct cccggacccc

tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac 840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag 900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac 960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc 1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc 1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa 1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac 1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc 1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag 1320gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa atga 1374211356DNAArtificial sequencenucleotide sequence of #29 fusion protein 21ccatattgga catccccaga aaagatggaa aagaaattgc atgcagtgcc ggctgccaag 60acagtgaagt tcaaatgccc ttccagtggg accccaaacc ccacactgcg ctggttgaaa 120aatggcaaag aattcaaacc tgaccacaga attggaggct acaaggtccg ttatgccacc 180tggagcatca taatggactc tgtggtgccc tctgacaagg gcaactacac ctgcattgtg 240gagaatgagt acggcagcat caaccacaca taccagctgg atgtcgtgga gcggtcccct 300caccggccca tcctgcaagc agggttgccc gccaacaaaa cagtggccct gggtagcaac 360gtggagttca tgtgtaaggt gtacagtgac ccgcagccgc acatccagtg gctaaagcac 420atcgaggtga atgggagcaa gattggccca gacaacctgc cttatgtcca gatcttgaag 480actgctggag ttaataccac cgacaaagag atggaggtgc ttcacttaag aaatgtctcc 540tttgaggacg caggggagta tacgtgcttg gcgggtaact ctatcggact ctcccatcac 600tctgcatggt tgaccgttct ggaagccctg gaagagaggc cggcagtgat gacctcgccc 660ctgtacctgg aggacaaaac tcacacatgc ccaccgtgcc cagcacctga actcctgggg 720ggaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc 780cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac 840tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac 900aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc 960aaggagtaca agtgcaaggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc 1020tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat 1080gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac 1140atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc 1200gtgctggact ccgacggctc cttcttcctc tacagcaagc tcaccgtgga caagagcagg 1260tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac 1320acgcagaaga gcctctccct gtctccgggt aaatga 1356221341DNAArtificial sequencenucleotide sequence of #8 fusion protein 22ccagaaaaga tggaaaagaa attgcatgca gtgccggctg ccaagacagt gaagttcaaa 60tgcccttcca gtgggacccc aaaccccaca ctgcgctggt tgaaaaatgg caaagaattc 120aaacctgacc acagaattgg aggctacaag gtccgttatg ccacctggag catcataatg 180gactctgtgg tgccctctga caagggcaac tacacctgca ttgtggagaa tgagtacggc 240agcatcaacc acacatacca gctggatgtc gtggagcggt cccctcaccg gcccatcctg 300caagcagggt tgcccgccaa caaaacagtg gccctgggta gcaacgtgga gttcatgtgt 360aaggtgtaca gtgacccgca gccgcacatc cagtggctaa agcacatcga ggtgaatggg 420agcaagattg gcccagacaa cctgccttat gtccagatct tgaagactgc tggagttaat 480accaccgaca aagagatgga ggtgcttcac ttaagaaatg tctcctttga ggacgcaggg 540gagtatacgt gcttggcggg taactctatc ggactctccc atcactctgc atggttgacc 600gttctggaag ccctggaaga gaggccggca gtgatgacct cgcccctgta cctggaggac 660aaaactcaca catgcccacc gtgcccagca cctgaactcc tggggggacc gtcagtcttc 720ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacatgc 780gtggtggtgg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc 840gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt 900gtggtcagcg tcctcaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc 960aaggtctcca acaaagccct cccagccccc atcgagaaaa ccatctccaa agccaaaggg 1020cagccccgag aaccacaggt gtacaccctg cccccatccc gggatgagct gaccaagaac 1080caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg 1140gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac 1200ggctccttct tcctctacag caagctcacc gtggacaaga gcaggtggca gcaggggaac 1260gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc 1320tccctgtctc cgggtaaatg a 13412378DNAHomo sapiensmisc_feature(1)..(78)DNA sequence of VEGFR1 signal peptide 23atggtcagct actgggacac cggggtcctg ctgtgcgcgc tgctcagctg tctgcttctc 60acaggatcta gttccgga 782432DNAArtificial sequenceforward primer DNA sequence of #19 fusion protein 24tagttccgga aggccgtccc cgaccttgcc tg 322532DNAArtificial sequenceforward primer of DNA sequence of #13 fusion protein 25tagttccgga aaaaatcgca cccgcatcac ag 322631DNAArtificial sequenceforward primer DNA sequence of #22 fusion protein 26tagttccgga gtaaccagca gcccctcggg c 312733DNAArtificial sequenceforward primer DNA sequence of #23 fusion protein 27tagttccgga tcctcttcag aggagaaaga aac 332832DNAArtificial sequenceforward primer DNA sequence of #26 fusion protein 28tagttccgga aaacctaacc ccgtagctcc at 322934DNAArtificial sequenceforward primer DNA sequence of #29 fusion protein 29tagttccgga ccatattgga catccccaga aaag 343036DNAArtificial sequenceforward primer DNA sequence of #8 fusion protein 30ctagctccgg accagaaaag atggaaaaga aattgc 363130DNAArtificial sequencereverse primer DNA sequence of FGFR1 31gttttgtcct ccaggtacag gggcgaggtc 303230DNAArtificial sequenceforward primer DNA sequence of human IgG Fc 32ctgtacctgg aggacaaaac tcacacatgc 303330DNAArtificial sequencereverse primer DNA sequence of human IgG Fc 33gatatctgca gtcatttacc cggagacagg 30

Claims

1. An isolated soluble fusion protein of fibroblast growth factor receptor (FGFR), comprising: a part derived from an intermediate functional sequence (IFS) of an Ig-like domain of FGFR, a second Ig-like domain (D2) of FGFR, a third Ig-like domain (D3) of FGFR, and an immunoglobulin Fc region.

2. The fusion protein of claim 1, which binds fibroblast growth factor (FGF).

3. The fusion protein of claim 1, wherein the part derived from IFS does not comprise an acidic box (AB).

4. The fusion protein of claim 1, wherein the part derived from IFS comprises the amino acid sequence corresponding to position 134 to position 162, position 145 to position 162, or position 151 to position 162 of SEQ ID NO: 1.

5. The fusion protein of claim 1, further comprising a first Ig-like domain (D1) of FGFR or a moiety thereof.

6. The fusion protein of claim 5, wherein the first Ig-like domain of FGFR or a moiety thereof comprises: an amino acid sequence corresponding to position 40 to position 118 of SEQ ID NO: 1, or an amino acid sequence having at least 70% identity with the sequence of position 40 to position 118 of SEQ ID NO: 1; or an amino acid sequence corresponding to position 77 to position 118 of SEQ ID NO: 1, or an amino acid sequence having at least 70% identity with the amino acid sequence of position 77 to position 118 of SEQ ID NO: 1.

7. The fusion protein of claim 1, wherein said D2 domain comprises an amino acid sequence corresponding to position 163 to position 247 of SEQ ID NO: 1, or an amino acid sequence having at least 70% identity with the amino acid sequence of position 163 to position 247 of SEQ ID NO: 1; and/or said D3 domain comprises an amino acid sequence corresponding to position 270 to position 359 of SEQ ID NO: 1, or an amino acid sequence having at least 70% identity with the amino acid sequence of position 270 to position 359 of SEQ ID NO: 1.

8. The fusion protein of claim 1, wherein the immunoglobulin Fc region is human IgG and comprises: an amino acid sequence of SEQ ID NO: 7, or an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO: 7; or an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 8, or an amino acid sequence encoded by a nucleotide sequence having at least 70% identity with the nucleotide sequence of SEQ ID NO: 8.

9. The fusion protein of claim 1, wherein one or more of the parts, domains and/or regions involved are linked by one or more linkers.

10. The fusion protein of claim 1, which comprises a part derived from an extracellular domain of FGFR and an immunoglobulin Fc region, wherein the part derived from the extracellular domain of FGFR comprises: (1) an amino acid sequence corresponding to positions 358-580 of SEQ ID NO: 9, positions 304-526 of SEQ ID NO: 10, positions 278-500 of SEQ ID NO: 11, positions 246-468 of SEQ ID NO: 12, positions 235-457 of SEQ ID NO: 13, positions 229-451 of SEQ ID NO: 14 or positions 224-446 of SEQ ID NO: 15, or is encoded by a nucleotide sequence corresponding to positions 1074-1740 of SEQ ID NO: 16, positions 912-1578 of SEQ ID NO: 17, positions 834-1500 of SEQ ID NO: 18, positions 738-1404 of SEQ ID NO: 19, positions 705-1371 of SEQ ID NO: 20, positions 687-1353 of SEQ ID NO: 21 or positions 672-1338 of SEQ ID NO: 22; (2) an amino acid sequence having at least 70% identity with the amino acid sequence corresponding to positions 358-580 of SEQ ID NO: 9, positions 304-526 of SEQ ID NO: 10, positions 278-500 of SEQ ID NO: 11, positions 246-468 of SEQ ID NO: 12, positions 235-457 of SEQ ID NO: 13, positions 229-451 of SEQ ID NO: 14 or positions 224-446 of SEQ ID NO: 15; or (3) an amino acid sequence encoded by a nucleotide sequence having at least 70% identity with a nucleotide sequence corresponding to positions 1074-1740 of SEQ ID NO: 16, positions 912-1578 of SEQ ID NO: 17, positions 834-1500 of SEQ ID NO: 18, positions 738-1404 of SEQ ID NO: 19, positions 705-1371 of SEQ ID NO: 20, positions 687-1353 of SEQ ID NO: 21 or positions 672-1338 of SEQ ID NO: 22.

11. The Fc fusion protein of claim 1, wherein said protein comprises: (1) an amino acid sequence indicated by any one of SEQ ID NOs: 9-15, or an amino acid sequence encoded by a nucleotide sequence indicated by any one of SEQ ID NOs: 16-22; (2) an amino acid sequence having at least 70% identity with an amino acid sequence indicated by any one of SEQ ID NOs: 9-15; or (3) an amino acid sequence encoded by a nucleotide sequence having at least 70% identity with the nucleotide sequence indicated by any one of SEQ ID NOs: 16-22.

12. An isolated nucleic acid molecule encoding the fusion protein of claim 1.

13. The nucleic acid molecule of claim 12, comprising a nucleotide sequence indicated by any one of SEQ ID NOs: 16-22.

14. A vector comprising the nucleic acid molecule of claim 12.

15. A cell transfected by the vector of claim 14.

16. A pharmaceutical composition, comprising the fusion protein of claim 1, and/or a nucleic acid molecule encoding said fusion protein, as well as a pharmaceutically acceptable carrier.

17. A method for producing an angiogenesis-inhibitory fusion protein, wherein said method comprises expressing the fusion protein of claim 1 in a cell.

18. A method for producing a medicament for the inhibition of angiogenesis, or for the prevention and/or treatment of tumors, wherein said method comprises the use of the fusion protein of claim 1, or a nucleic acid molecule encoding said fusion protein.

19. A method for inhibiting angiogenesis in a subject or for the treatment and/or prevention of a tumor in a subject, wherein said method comprises administering, to a subject in need of such inhibition, prevention, and/or treatment, an effective amount of a fusion protein of claim 1 and/or a nucleic acid molecule encoding said fusion protein.

20. A method for binding FGF in vitro or in vivo, which comprises contacting FGF to a fusion protein of claim 1.